CA2661662A1 - Methods of screening for agents that inhibit binding between mphosph1 and prc1 - Google Patents

Abstract

The present invention provides a method of identifying agents that inhibit or suppress the binding between MPHOSPH1 and PRC1. Such agents are expected to suppress the proliferation of cell expressing MPHOSPH1 and PRC1, and function as agents to prevent or treat cancer, such as bladder cancer.

Description

DESCRIPTION

METHODS OF SCREENING FOR AGENTS THAT INHIBIT BINDING BETWEEN

This application claims the benefit of U.S. Provisional Application Serial No.
60/840,124 filed August 25 2006, the contents of which are hereby incorporated by reference in their entirety.

FIELD OF THE INVENTION
The present invention relates to screening methods using the binding of M-phase phosphoprotein 1(MPHOSPHI) to Protein regulator of cytokinesis 1(PRC1) as an index.
Agents applicable for treating or preventing cancer, in particular bladder cancer, can be identified through the methods.

BACKGROUND OF THE INVENTION

Bladder cancer is the second most common genitourinary tumor in human populations, having an incidence of approximately 357,000 new cases each year worldwide (Parkin DM et al., CA Cancer J Clin 2005, 55: 74-108). About a third of the patients are suspected to suffer from invasive or metastatic disease at the time of diagnosis (Parkin DM et al., CA Cancer J
Clin 2005, 55: 74-108; Sternberg CN, Ann Oncol 1995, 6: 113-26; Ardavanis A et al., Br J
Cancer 2005, 92: 645-50). Although radical cystectomy is considered the'"gold standard" for the treatment of patients with localized but muscle-invasive bladder cancer, about 50% of such patients develop metastases within two years after cystectomy and subsequently die of the disease (Sternberg CN, Ann Oncol 1995, 6: 113-26).

In the last two decades, cisplatin-based combination chemotherapy regimens, such as CMV (cisplatin, methotrexate, and vinblastine) and M-VAC (methotrexate, vinblastine, doxorubicin, and cisplatin), have been primarily applied to patients with advanced bladder cancers (Ardavanis A et al., Br J Cancer 2005, 92: 645-50; Lehmann J et al., World J Urol 2002, 20: 144-50). However, the overall prognosis remains very poor. Moreover, side effects of M-VAC chemotherapy are significantly severe (Vaughn DJ, Semin Oncol 1999, 26(suppl 2): 117-22). Therefore, the development of new molecular target drugs against bladder cancer is earnestly desired.

cDNA microarray has been proven to be an effective tool for simultaneously analyzing the expression patterns of thousands of genes. Comparison of genome-wide expression profiles between cancers and normal cells by cDNA microarray provides useful information that enables the discovery candidate target molecules for development of diagnosis and treatment of cancer (Debouck C et al., Nat Genet 1999, 21: 48-50). Recent drug development investigations have focused on targeting important molecules involved in the oncogenic pathways, represented by imatinib, mesylate and trastuzumab. The combination of cancer-expression profiling with RNAi should enable the identification of such drug targets for therapy (Clarke PA et al., Eur J Cancer 2004, 40: 2560-91).

Through genome-wide expression analysis, a number of oncogenes involved in development and/or progression of hepatocellular carcinomas (Hamamoto R et al., Nat Cell Biol 2004, 6: 731-40; Yagyu R et al., Int J Oncol 2002, 20: 1173-8), synovial sarcomas (Nagayama S et al., Oncogene 2004, 23: 5551-7; Nagayama S et al., Oncogene 2005, 24:
6201-12), renal cell carcinomas (Togashi A et al., Cancer Res 2005, 65: 4817-26), and breast cancers (WO 2005/28676) have been isolated. Such molecules are considered to be good candidate molecules for development of new therapeutic modalities.

Since cytotoxic drugs, such as M-VAC, often cause severe adverse reactions, it is obvious that thoughtful selection of novel target molecules on the basis of well-characterized mechanisms of action should be very helpful to develop effective anti-cancer drugs having minimal risk of side effects. Toward this goal, expression profile analysis on 26 bladder cancers and 29 normal human tissue was previously performed, which, in turn, led to the discovery of multiple genes that are specifically over-expressed in bladder cancer (Takata R et al., Clin Cancer Res April 1, 2005, 11(7): 2625-36; Saito-Hisaminato A et al., DNA Res 2002, 9: 35-45). MPHOSPHI (referred to as C2093) was identified as one of the genes over-expressed in bladder cancer.

In addition, MPHOSPHI was previously identified as a protein that is specifically phosphorylated at G2/M transition, and therefore characterized as a plus-end-directed kinesin related protein (Abaza A et al., J Biol Chem 2003, 278: 27844-52). The MPHOSPHI cDNA
encodes a 1780-amino acid protein that is composed of three domains characteristic of an NH2-type kinesin-related protein: an NH2-kinesin motor domain, a central coiled coil-stalk domain, and a C-globular tail domain. Moreover, MPHOSPHI was previously documented to be plus-end-directed molecular motor with a crucial role in cytokinesis, and to accumulate in the midzone of the spindle during anaphase to telophase in HeLa cells (Abaza A et al., J
Biol Chem 2003, 278: 27844-52; Kamimoto T et al., J Biol Chem 2001, 276: 37520-8).

PRC 1 was reported to interact with several kinesin family proteins (Ban R et al., J Biol Chem 2004, 279:16394-402; Kurasawa Y et al., EMBO J 2004, 23: 3237-48; Zhu C &
Jiang W, Proc Natl Acad Sci USA 2005, 102: 343-8; Gruneberg U et al., J Cell Biol 2006, 172:
363-72). Suppression ofPRCI by anti-PRCI antibodies in HeLa cells is reported to cause an increase of bi-nucleated cells (Mollinari C et al., J Cell Biol 2002, 157:
1175-86). Further, it has been reported that PRC 1 could interact with several molecules, for example KIF4 or KIF14, which are associated with mitotic events, especially cytokinesis (Kurasawa Y et al., EMBO J 2004, 23: 3237-48; Mollinari C et al., Mol Biol Cell 2005, 16: 1043-55). Moreover, PRC 1 was identified by the present inventors to be over-expressed in breast cancer (WO
2005/28676).

SUMMARY OF THE INVENTION
The present invention is based, at least in part, on the discovery of the interaction between MPHOSPHI and PRC1 in vivo. Both proteins, MPHOSPHI and PRC1, are over-expressed in bladder cancer cells, and the expression of MPHOSPHI is only observed in bladder cancer cells and normal testis tissue. As demonstrated herein, the inhibition of one of the genes coding for these proteins suppresses cytokinesis and induces multinuclearization, which, in turn, ultimately leads to suppression of the proliferation of cells expressing the genes.

Accordingly, the present invention provides a method of screening for an agent that inhibits the binding between MPHOSPHI and PRC1. More specifically, the method includes the steps of: a) contacting MPHOSPHI with PRC 1 in the presence of an agent;
b) detecting the level of binding level between MPHOSPHI and PRCI; c) comparing the binding level of MPHOSPHI and PRC 1 with that detected in the absence of the agent; and d) selecting the agent that reduces the binding level of MPHOSPHI and PRC 1. In the context of this method, fragments may be used in place of the full-length MPHOSPHI or full-length PRC1, so long as each fragment retains the ability to bind to its partner ligand.
Particularly preferred fragments of MPHOSPHI to be used for the present screening include those including the amino acid residues 1188 to 1718 of SEQ ID NO: 2.

Given that the agents identified through the above mentioned method are likely to suppress the proliferation of cells expressing the proteins, such identified agents serve as candidates for treating or preventing bladder cancer. Thus, the present invention also provides methods of identifying agents that suppress the proliferation of bladder cancer cells as well as agents for treating or preventing bladder cancer.

BRIEF DESCRIPTION OF THE DRAWINGS
Figure 1 depicts the expression of MPHOSPHI in bladder cancer and normal tissues.
Panel A depicts the expression ofMPHOSPHI in tumor cells from 10 bladder cancer patients and normal human tissues (microdissected normal bladder transitional cells, heart, lung, liver and kidney) examined by semi-quantitative RT-PCR. The expression of GAPDH
served as a quantity control. Panel B depicts the results of Northern blot analysis of the MPHOSPHI
transcript in bladder cancer cell lines (HT1197, UMUC3, J82, HT1376, SW780 and RT4) and normal human organs (heart, lung, liver, kidney, brain, pancreas, testis and bladder). Panel C depicts the results of Northern blot analysis of the MPHOSPHI transcript in various human tissues. Panel D depicts the expression of MPHOSPHI protein in surgically resected bladder cancer tissues (2 superficial bladder cancer and 2 invasive bladder cancer cases) and normal bladder tissue sections by immunohistochemical staining using affinity-purified anti-MPHOSPHI polyclonal antibody.
Figure 2 depicts the subcellular localization of endogenous MPHOSPHI protein in bladder cancer cells during cell cycle. UMUC cells were immunohistochemically stained with affinity-purified MPHOSPHI polyclonal antibody (green). DAPI (blue) reveals nuclear staining.
Figure 3 depicts the growth inhibitory effects of MPHOSPHI-siRNA on bladder cancer cell lines, J82 and UMUC3. Panel A depicts the expression of MPHOSPHI
by Western blot (upper panel) and semi-quantitative RT-PCR (lower panel). Panel B
depicts the results of colony formation assays performed on J82 and UMUC3 cells transfected with plasmids expressing MPHOSPHI-siRNA, a control siRNA (EGFP), or MPHOSPHI
mismatch siRNA. Panel C depicts the viability of J82 and UMUC3 cells evaluated by MTT
assays in response to MPHOSPHI-siRNA introduction in comparison with the introduction of the control.
Figure 4 depicts the growth-promoting effect of exogenous MPHOSPHI in NIH3T3 cells. Panel A depicts the results of Western blot analysis on cells expressing high levels of exogenous MPHOSPHI or those transfected with mock vector. Exogenous introduced MPHOSPHI expression was validated with anti-HA-tag monoclonal antibody. Beta-actin served as a loading control. Panel B depicts the in vitro growth of NIH3T3-cells. The growth of NIH3T3 cells transfected with MPHOSPHI (NIH3T3-MPHOSPHI-#1, -#2, -#3) and mock (NIH3T3-Mock-#1, -#2, -#3) were measured by MTT assay. In Panel C, NIH3T3-MPHOSPHI (NIH3T3-MPHOSPHI-#1) and -mock (NIH3T3 -Mock-# 1) were synchronized by treatment of aphidicoline for 24 hr. After release, cell samples were prepared at the indicated time points. Panel D depicts the results of an in vivo tumor growth assay performed on NIH3T3-MPHOSPHI cells. The diameters of the tumors were measured by calipers and the tumor volumes were determined using the following formula;
0.5 x (larger diameter) x (smaller diameter)2. Unpaired t-test was performed to evaluate the difference between NIH3T3-MPHOSPHI and NIH3T3-Mock on day 21 post-injection. (p < 0.001;
unpaired t-test).
Figure 5 depicts the interaction between MPHOSPHI and PRC 1. Panel A depicts the expression of MPHOSPHI and PRC 1 in bladder cancer cases by semi-quantitative RT-PCR.
Expression of GAPDH served as a quantity control. Panel B depicts the co-immunoprecipitation of MPHOSPHI and PRC 1. Cell lysates from COS7 cells transfected with HA tagged MPHOSPHI and myc tagged PRC1 proteins were immunoprecipitated with anti-HA or anti-myc. Immunoprecipitates were immunoblotted using monoclonal anti-HA or anti-myc antibodies. Panel C depicts the subcellular localization of endogenous MPHOSPHI
and exogenous PRC1 in UMUC3 cells. Endogenous MPHOSPHI protein (green) co-localized with exogenous PRC 1 protein (red).
Figure 6 depicts the determined regions of MPHOSPHI that interact with PRC 1.
Panel A is a schematic illustration of the MPHOSPHI fragments and full-length used for immunoprecipitation experiments. Panel B depicts the co-immunoprecipitation of a series of fragments of MPHOSPHI and PRC I. Cell lysates from COS7 cells transfected with HA
tagged MPHOSPHI and myc tagged PRC1 proteins were immunoprecipitated with anti-HA
or anti-myc. Immunoprecipitates were immunoblotted using monoclonal anti-HA or anti-myc antibodies as described in the legend of Fig.5.

Figure 7 depicts the significant role of MPHOSPHI and PRC 1 in cell proliferation of bladder cancer. Panel A depicts the effects of si-PRC 1 or control siRNA (si-EGFP) on J82 cells, analyzed by semi-quantitative RT-PCR (top left), colony formation assays (bottom left), or MTT assays (right). Panel B depicts the effects of si-PRC1 or control siRNA
(si-EGFP) on UMUC3 cells, analyzed by semi-quantitative RT-PCR (top left), colony formation assays (bottom left) or MTT assays (right). Panel C depicts the morphology of UMUC
cells transfected with si-MPHOSPHI, si-PRC I or si-EGFP as a control. Morphology of UMUC
cells transfected si-MPHOSPHI, si-PRC I or si-EGFP as a control siRNA was observed under microscope (upper panel) or evaluated by immunocytochemistry (bottom panel).
UMUC

cells treated by siRNAs were stained with DAPI and phalloidin in order to distinguish nuclear and cytoplasm.

DETAILED DESCRIPTION OF THE fNVENTION
Among up-regulated genes in bladder cancers detected by microarray analysis, the present invention focuses on MPHOSPHI (M-phase phosphoprotein 1) (SEQ ID NO:
1) (NM_016195), a gene that is highly over-expressed in a great majority of the examined bladder cancer cells. Northern blot analysis showed that the expression ofMPHOSPHI was barely detectable in any of the examined normal human tissues except testis.
Further, immunohistochemical staining experiments using anti-MPHOSPHI polyclonal antibody clearly indicated the up-regulation of MPHOSPHI (SEQ ID NO: 2) expression in bladder cancer cells, suggesting that MPHOSPHI is a cancer-testis antigen (Kanehira M
et al., Cancer Res. 2007, 67 (7): 3276-85). Together, these results suggest that the MPHOSPHI
gene may serve as a valuable target for the development of anti-cancer agents or cancer peptide-vaccine for bladder cancers.
Furthermore, immunocytochemical staining experiments demonstrated that MPHOSPHI was localized in the nucleus of bladder cancer cells at interphase, in the midzone at late anaphase, and on the contractile ring at telophase. Moreover, knockdown of endogenous MPHOSPHI by siRNAs was demonstrated to induce failure of cytokinesis in bladder cancer cells and result in accumulation of multi-nuclear cells leading to subsequent cell death. Hence, biological roles of MPHOSPHI in bladder cancer cells were examined by identification of its interacting protein(s).
MPHOSPHI was found to interact with PRC1 (SEQ ID NO: 37 encoded by SEQ ID
NO: 36) (AF044588) (Protein Regulator of Cytokinesis 1), a gene whose expression is also up-regulated in bladder cancers. Due to their functional similarity and common over-expression in bladder cancer cells, PRC 1 was selected as a candidate to interact with MPHOSPHI. As shown in Fig. 5, in vivo interaction and co-localization of MPHOSPHI and PRC1 (Protein regulator of cytokinesis 1) were demonstrated during interphase to anaphase in bladder cancer cells, while MPHOSPHI surrounded PRC1 that localized in the center of midbody in telophase cells (Fig. 5C). Thus, the association and co-localization of MPHOSPHI and PRCI on the mitotic spindle further support the proposition that MPHOSPHI is a motor protein that translocates PRC1 along the mitotic spindles during mitosis. Their co-transactivation in bladder cancer cases (Fig. 5A) suggest that their interaction play a crucial role in bladder carcinogenesis.

Moreover, suppression of either ofMPHOSPHI or PRCI expression using specific siRNAs thereto induced the formation of multi-nucleated cells, followed by cell death. To assess whether MPHOSPHI or PRC1 plays a role in the growth or survival of bladder cancer cells, the expression of either endogenous MPHOSPHI or PRC 1 was knocked down with specific-siRNAs in bladder cancer lines, J82 or UMUC3 that showed high levels of expression of MPHOSPHI and PRC 1. Each of the specific siRNAs significantly suppressed the expression of corresponding genes, and resulted in significant growth suppression of these cells, indicating that both MPHOSPHI and PRC 1 are essential for the growth of bladder cancer cells. Moreover, knockdown of MPHOSPHI or PRC1 expression in UMUC3 cells caused significant increase of the multi-nucleated cells. These results support the suggestion in the literature that suppression of PRC 1 by microinjection of anti-PRC 1 antibodies into HeLa cells can cause an increase of bi-nucleated cells (Mollinari C et al., J
Cell Biol 2002, 157: 1175-86). Since inhibition of their interaction may finally lead to cell death after the failure of cytokinesis in bladder cancer cells, an agent that inhibits their interaction would serve as a valuable target for the development of pharmaceuticals against bladder cancer.
The microarray data obtained by the present inventors revealed exclusive over-expression of MPHOSPHI in bladder cancers. However, the protein PRC1, which was discovered to interact with MPHOSPHI, was not only over-expressed in bladder cancer cells but also in several other types of human tumors (data not shown). While it has been reported that PRC1 could interact with several molecules, for example KIF4 or KIF14, which are associated with mitotic events, especially cytokinesis (Kurasawa Y et al., EMBO J 2004, 23:
3237-48; Mollinari C et al., Mol Biol Cell 2005, 16: 1043-55), neither KIF4 nor KIF14 was expressed in bladder cancers according to the expression profiles of bladder cancers obtained by the present inventors. These results suggest that regulation of cytokinesis by stabilizing the midozone microtubule bundles and permitting completion of cell cleavage through the interaction of MPHOSPHI and PRC 1 is an event specific to bladder cancer cells, although the roles of this interaction for cell proliferation and the presence of other binding partners still remain to be elucidated.

Finally, the present findings suggest that the MPHOSPHI/PRC1 pathway is likely to have an oncogenic function in bladder cancer cells, and may be a promising molecular target for the development of anti-cancer drugs against bladder cancer. The development of agents to suppress or inhibit the binding of MPHOSPHI with PRC 1 may be a rational strategy for bladder cancer therapy. Although further analysis on the binding between MPHOSPHI and PRC I may be needed, the evidence provided herein contributes to more profound understanding of bladder cancer carcinogenesis and to develop novel therapies for bladder cancers.

The words "a", "an", and "the" as used herein mean "at least one" unless otherwise specifically indicated.
The terms "isolated" and "purified" used herein in relation to a substance (e.g., polypeptide, antibody, polynucleotide, etc.) indicate that the substance is substantially free from at least one substance that may else be included in the natural source.
Thus, an isolated or purified antibody refers to antibodies that is substantially free of cellular material such as carbohydrate, lipid, or other contaminating proteins from the cell or tissue source from which the protein (antibody) is derived, or substantially free of chemical precursors or other chemicals when chemically synthesized. The term "substantially free of cellular material"
includes preparations of a polypeptide in which the polypeptide is separated from cellular components of the cells from which it is isolated or recombinantly produced.
Thus, a polypeptide that is substantially free of cellular material includes preparations of polypeptide having less than about 30%, 20%, 10%, or 5% (by dry weight) of heterologous protein (also referred to herein as a "contaminating protein"). When the polypeptide is recombinantly produced, it is also preferably substantially free of culture medium, which includes preparations of polypeptide with culture medium less than about 20%, 10%, or 5% of the volume of the protein preparation. When the polypeptide is produced by chemical synthesis, it is preferably substantially free of chemical precursors or other chemicals, which includes preparations of polypeptide with chemical precursors or other chemicals involved in the synthesis of the protein less than about 30%, 20%, 10%, 5% (by dry weight) of the volume of the protein preparation. That a particular protein preparation contains an isolated or purified polypeptide can be shown, for example, by the appearance of a single band following sodium dodecyl sulfate (SDS)-polyacrylamide gel electrophoresis of the proteiri preparation and Coomassie Brilliant Blue staining or the like of the gel. In a preferred embodiment, antibodies of the present invention are isolated or purified.
An "isolated" or "purified" nucleic acid molecule, such as a cDNA molecule, can be substantially free of other cellular material or culture medium when produced by recombinant techniques, or substantially free of chemical precursors or other chemicals when chemically synthesized. In a preferred embodiment, nucleic acid molecules encoding antibodies of the present invention are isolated or purified.

The terms "polypeptide", "peptide" and "protein" are used interchangeably herein to refer to a polymer of amino acid residues. The terms apply to amino acid polymers in which one or more amino acid residue is a modified residue, or a non-naturally occurring residue, such as an artificial chemical mimetic of a corresponding naturally occurring amino acid, as well as to naturally occurring amino acid polymers.
The term "amino acid" refers to naturally occurring and synthetic amino acids, as well as amino acid analogs and amino acid mimetics that similarly functions to the naturally occurring amino acids. Naturally occurring amino acids are those encoded by the genetic code, as well as those modified after translation in cells (e.g., hydroxyproline, y-carboxyglutamate, and 0-phosphoserine). The phrase "amino acid analog" refers to compounds that have the same basic chemical structure (an a carbon bound to a hydrogen, a carboxy group, an amino group, and an R group) as a naturally occurring amino acid but have a modified R group or modified backbones (e.g., homoserine, norleucine, methionine, sulfoxide, methionine methyl sulfonium). The phrase "amino acid mimetic"
refers to chemical compounds that have different structures but similar functions to general amino acids.
Amino acids may be referred to herein by their commonly known three letter symbols or the one-letter symbols recommended by the IUPAC-IUB Biochemical Nomenclature Commission.
The terms "polynucleotides", "nucleotides", "nucleic acids", and "nucleic acid molecules" are used interchangeably unless otherwise specifically indicated and, similarly to the amino acids, are referred to by their commonly accepted single-letter codes. Similar to the amino acids, they encompass both naturally-occurring and non-naturally occurring nucleic acid polymers.
The nucleotide sequence of the human MPHOSPHl gene is shown in SEQ ID NO:
1(GenBank Accession NM_016195). Herein, the phrase "MPHOSPHI gene" encompasses the human MPHOSPHI gene as well as those of other animals including non-human primate, mouse, rat, dog, cat, horse, and cow. However, the present invention is not limited thereto, and includes allelic mutants and genes found in other animals as corresponding to the MPHOSPHI gene.
The amino acid sequence encoded by the human MPHOSPHI gene is shown in SEQ ID NO: 2 (GenBank Accession NP_057279.2). Herein, the polypeptide encoded by the MPHOSPHI gene is referred to as LLMPHOSPHI", and sometimes as "MPHOSPHI

polypeptide" or "MPHOSPHI protein".
The nucleotide sequence of human PRC1 gene is shown in SEQ ID NO: 36.
Furthermore, three different transcriptional variants, composed of 15, 14, and 14 exons, respectively, are known in the art. The nucleotide and amino acid sequences of the variants can be found in GenBank (herein below, the variant with the sequences GenBank Accession No. NM_003981, NM_199413, and NM_199414 are referred to as V1, V2 and V3, respectively; and corresponding amino acid sequences can be found as GenBank Accession Nos. NP003972.1, NP_955445. l, and NP_955446.1, respectively). Except alternative variations in exon 13 and 14 of V 1, all other exons were common to the three variants. V2 variant has no exon 14 of V I, and a novel early stop codon is included within the last exon.
Exon 14 of V3 variant was completely deleted, exon 13 of V3 was 77bp shorter at the 3' end than that of V I, and included a novel early stop codon within the last exon.
The variants V I, V2, and V3 respectively encode proteins of 620, 606, and 566 amino acids.
Herein, the phrase "PRCI gene" encompasses all of the human PRCI gene variants as well as those of other animals including non-human primate, mouse, rat, dog, cat, horse, and cow but is not limited thereto, and includes allelic mutants and genes found in other animals as corresponding to the PRC1 gene.
The amino acid sequence encoded by the human PRCI gene is shown in SEQ ID
NO: 37. Herein, the polypeptide encoded by the PRCI gene is referred to as "PRC 1", and sometimes as "PRC 1 polypeptide" or "PRC 1 protein".
According to an aspect of the present invention, functional equivalents are also considered "MPHOSPHI polypeptides" and "PRC 1 polypeptides". Herein, a "functional equivalent" of a protein is a polypeptide that has a biological activity, in particular, the binding activity equivalent to the protein. Namely, any polypeptide that retains the activity of the MPHOSPH 1 protein to the PRC 1 protein, or the activity of the PRC 1 protein to the MPHOSPHI protein may be used as such a functional equivalent of the polypeptides in the present invention. Such functional equivalents include those wherein one or more amino acids are substituted, deleted, added, or inserted to the natural occurring amino acid sequence of the MPHOSPH 1 or PRC 1 protein.
Generally, it is known that modifications of one or more amino acid in a protein do not influence the function of the protein (Mark DF et al., Proc Natl Acad Sci USA 1984, 81:
5662-6; Zoller MJ & Smith M, Nucleic Acids Res 1982, 10: 6487-500; Wang A et al., Science 1984, 224:1431-3; Dalbadie-McFarland G et al., Proc Natl Acad Sci USA
1982, 79:

6409-13). In fact, mutated or modified proteins, proteins having amino acid sequences modified by substituting, deleting, inserting, and/or adding one or more amino acid residues of a certain amino acid sequence, have been known to retain the original biological activity (Mark et al., Proc Natl Acad Sci USA 81: 5662-6 (1984); Zoller and Smith, Nucleic Acids Res 10:6487-500 (1982); Dalbadie-McFarland et al., Proc Natl Acad Sci USA 79:

(1982)). Accordingly, one of skill in the art will recognize that individual additions, deletions, insertions, or substitutions to an amino acid sequence which alter a single amino acid or a small percentage of amino acids, or those considered to be "conservative modifications", wherein the alteration of a protein results in a protein with similar functions, are contemplated in the context of the instant invention.
So long as the activity the protein is maintained, the number of amino acid mutations is not particularly limited. However, it is generally preferred to alter 5% or less of the amino -acid sequence. Accordingly, in a preferred embodiment, the number of amino acids to be mutated in such a mutant is generally 30 amino acids or less, preferably 20 amino acids or less, more preferably 10 amino acids or less, more preferably 6 amino acids or less, and even more preferably 3 amino acids or less.
An amino acid residue to be mutated is preferably mutated into a different amino acid in which the properties of the amino acid side-chain are conserved (a process known as conservative amino acid substitution). Examples of properties of amino acid side chains are hydrophobic amino acids (alanine, isoleucine, leucine, methionine, phenylalanine, proline, tryptophan, tyrosine, valine), hydrophilic amino acids (arginine, aspartic acid, aspargin, cystein, glutamic acid, glutamine, glycine, histitidine, lysine, serine, threonine), and side chains having the following functional groups or characteristics in common: an aliphatic side-chain (glycine, alanine, valine, leucine, isoleucine, praline); a hydroxyl group containing side-chain (serine, threonine, tyrosine); a sulfur atom containing side-chain (C, M); a carboxylic acid and amide containing side-chain (aspartic acid, aspargine, glutamic acid, glutamine); a base containing side-chain (arginine, lysine, histidine);
and an aromatic containing side-chain (histidine, phenylalanine, tyrosine, tryptophan).
Furthermore, conservative substitution tables providing functionally similar amino acids are well known in the art. For example, the following eight groups each contain amino acids that are conservative substitutions for one another:
1) Alanine (A), Glycine (G);
2) Aspartic acid (D), Glutamic acid (E);

3) Aspargine (N), Glutamine (Q);
4) Arginine (R), Lysine (K);
5) Isoleucine (I), Leucine (L), Methionine (M), Valine (V);
6) Phenylalanine (F), Tyrosine (Y), Tryptophan (W);
7) Serine (S), Threonine (T); and 8) Cystein (C), Methionine (M) (see, e.g., Creighton, Proteins 1984).
Such conservatively modified polypeptides are included in the present MPHOSPHI
or PRC 1 protein. However, the present invention is not restricted thereto and the MPHOSPHI and PRC1 proteins include non-conservative modifications so long as the binding activity of the original proteins is retained. Furthermore, the modified proteins do not exclude polymorphic variants, interspecies homologues, and those encoded by alleles of these proteins.
An example of a protein modified by addition of one or more amino acids residues is a fusion protein. Fusion proteins are fusions of the MPHOSPHI or PRC 1 protein and other peptides or proteins, which also can be used in the present invention.
Fusion proteins can be made by techniques well known to a person skilled in the art, such as by linking the DNA encoding the MPHOSPHI or PRC 1 protein with a DNA encoding other peptides or proteins, so that the frames match, inserting the fusion DNA into an expression vector and expressing it in a host. There is no restriction as to the peptides or proteins fused to the MPHOSPHI or PRC1 protein so long as the resulting fusion proteins retain the activity of the original proteins to bind to each other.
Known peptides that can be used as peptides to be fused to the MPHOSPHI or PRC1 protein include, for example, FLAG (Hopp TP et al., Biotechnology 1988 6:
1204-10), 6xHis containing six His (histidine) residues, lOxHis, Influenza agglutinin (HA), human c-myc fragment, VSP-GP fragment, p18HIV fragment, T7-tag, HSV-tag, E-tag, SV40T
antigen fragment, lck tag, a-tubulin fragment, B-tag, Protein C fragment, and the like. Examples of proteins that may be fused to a protein of the invention include GST
(glutathione-S-transferase), Influenza agglutinin (HA), immunoglobulin constant region, 0-galactosidase, MBP (maltose-binding protein), and such.
Fusion proteins can be prepared by fusing commercially available DNA, encoding the fusion peptides or proteins discussed above, with the DNA encoding the MPHOSPHI or PRC 1 protein and expressing the fused DNA prepared.
Furthermore, the modified proteins do not exclude polymorphic variants, interspecies homologues, and those encoded by alleles of these proteins.
An alternative method known in the art to isolate functional equivalent proteins is, for example, the method using a hybridization technique (Sambrook J et al., Molecular Cloning 2nd ed. 9.47-9.58, Cold Spring Harbor Lab. Press, 1989). One skilled in the art can readily isolate a DNA having high homology with a whole or part of the human MPHOSPHIor PRCI DNA sequence (e.g., SEQ ID NO: 1 or 36) encoding the human MPHOSPHI or PRC1 protein, and isolate functional equivalent proteins to the human MPHOSPHI or PRC 1 protein from the isolated DNA. Thus, the proteins used for the present invention include those that are encoded by DNA that hybridize under stringent conditions with a whole or part of the DNA sequence encoding the human MPHOSPHI or PRC1 protein and are functional equivalent to the human MPHOSPHI or PRC1 protein.
These proteins include mammal homologues corresponding to the protein derived from human or mouse (for example, a protein encoded by a monkey, rat, rabbit and bovine gene).
In isolating a cDNA highly homologous to the DNA encoding the human MPHOSPHI
protein from animals, it is particularly preferable to use tissues from testis, or bladder cancer.
On the other hand, in isolating a cDNA highly homologous to the DNA encoding the human PRC1 protein from animals, in addition to the tissues from testis and bladder cancer, tissues from breast cancer may also be used.
The condition of hybridization for isolating a DNA encoding a protein functional equivalent to the human MPHOSPHI or PRC 1 protein can be routinely selected by a person skilled in the art. The phrase "stringent (hybridization) conditions" refers to conditions under which a nucleic acid molecule will hybridize to its target sequence, typically in a complex mixture of nucleic acids, but not detectably to other sequences. Stringent conditions are sequence-dependent and will be different in different circumstances. Longer sequences hybridize specifically at higher temperatures. An extensive guide to the hybridization of nucleic acids is found in Tijssen, Techniques in Biochemistry andMolecular Biology--Hybridization with Nitcleic Probes, "Overview of principles of hybridization and the strategy of nucleic acid assays" (1993). Generally, stringent conditions are selected to be about 5-10 C lower than the thermal melting point (Tm) for the specific sequence at a defined ionic strength pH. The Tm is the temperature (under defined ionic strength, pH, and nucleic concentration) at which 50% of the probes complementary to the target hybridize to the target sequence at equilibrium (as the target sequences are present in excess, at Tm, 50% of the probes are occupied at equilibrium). Stringent conditions may also be achieved with the addition of destabilizing agents such as formamide. For selective or specific hybridization, a positive signal is at least two times of background, preferably 10 times of background hybridization. Exemplary stringent hybridization conditions include the following: 50%
formamide, 5x SSC, and 1% SDS, incubating at 42 C, or, 5x SSC, 1% SDS, incubating at 65 C, with wash in 0.2x SSC, and 0.1% SDS at 50 C.

In the context of the present invention, a suitable condition of hybridization for isolating a DNA encoding a polypeptide functionally equivalent to the human MPHOSPHl or PRC 1 protein can be routinely selected by a person skilled in the art. For example, hybridization may be performed by conducting prehybridization at 68 C for 30 min or longer using "Rapid-hyb buffer" (Amersham LIFE SCIENCE), adding a labeled probe, and warming at 68 C for 1 h or longer. The following washing step can be conducted, for example, in a low stringent condition. An exemplary low stringency condition may include, for example, 42 C, 2x SSC, 0.1% SDS, or preferably 50 C, 2x SSC, 0.1% SDS.
More preferably, a high stringency condition is used. An exemplary high stringent condition may include, for example, washing 3 times in 2x SSC, 0.01% SDS at room temperature for 20 min, then washing 3 times in lx SSC, 0.1% SDS at 37 C for 20 min, and washing twice in lx SSC, 0.1% SDS at 50 C for 20 min. However, several factors such as temperature and salt concentration can influence the stringency of hybridization and one skilled in the art can suitably select the factors to achieve the requisite stringency.
In place of hybridization, a gene amplification method, for example, the polymerase chain reaction (PCR) method, can be utilized to isolate a DNA encoding a protein functional equivalent to the human MPHOSPHI or PRC1 protein, using a primer synthesized based on the sequence information of the DNA (SEQ ID NO: 1 for MPHOSPHI and SEQ ID NO:

for PRC1) encoding the human MPHOSPHI or PRC1 protein (SEQ ID NO: 2 or 37).
Proteins that are functional equivalent to the human MPHOSPHI or PRC 1 protein encoded by the DNA isolated through the above hybridization techniques or gene amplification techniques, normally have a high homology (also referred to as sequence identity) to the amino acid sequence of the human MPHOSPHI or PRCI protein.
"High homology" (also referred to as "high identity") typically refers to the degree of identity between two optimally aligned sequences (either polypeptide or polynucleotide sequences).
Typically, high homology or identity refers to homology of 40% or higher, preferably 60%
or higher, more preferably 80% or higher, even more preferably 85%, 90%, 95%, 98%, 99%, or higher. The degree of homology or identity between two polypeptide or polynucleotide sequences can be determined by following the algorithm in "Wilbur, WJ & Lipman DJ, Proc Natl Acad Sci USA 1983, 80: 726-30".
A protein useful in the context of the present invention may have variations in amino acid sequence, molecular weight, isoelectric point, the presence or absence of sugar chains, or form, depending on the cell or host used to produce it or the purification method utilized. Nevertheless, so long as it retains the binding activity possessed by the corresponding natural protein (MPHOSPHI (SEQ ID NO: 1) or PRCI (SEQ ID NO:
37)), it is useful in the present invention.
The present invention also encompasses the use of partial peptides of the MPHOSPHI or PRC1 protein. A partial peptide has an amino acid sequence specific to the protein of the MPHOSPHI or PRC 1 and is composed of less than about 400 amino acids, usually less than about 200 and often less than about 100 amino acids, and at least about 7 amino acids, preferably about 8 amino acids or more, and more preferably about 9 amino acids or more. A partial peptide of MPHOSPHI used for the screenings of the present invention suitably contains at least the binding site to PRC 1 of the MPHOSPHI
protein, and a partial peptide of PRC 1 used for the screenings of the present invention suitably contains at least the binding site to MPHOSPHI of the PRC1 protein. Such partial peptides are also encompassed by the phrase "functional equivalent" of the MPHOSPHI or PRC1 protein.
The present inventors revealed that amino acid residues from 1188 to 1465 and 1662 to 1718 of SEQ ID NO: 2 function as the binding region of MPHOSPHI to PRC
1.
Therefore, a partial peptide of MPHOSPHI to be used for the present screenings should contain at least the amino acid residues from 1188 to 1465 or 1662 to 1718 of SEQ ID NO: 2.
Moreover, according to a preferable embodiment of the present invention, the MPHOSPHI
protein used for the screening methods includes at least the amino acid residues 1188 to 1718 of SEQ ID NO: 2.

Moreover, in the context of the present invention, the phrase "MPHOSPHI gene"
encompasses polynucleotides that encode the MPHOSPHI protein or any of the functional equivalents of the MPHOSPHI protein. Similarly, the phrase "PRCI gene"
encompasses polynucleotides that encode the PRC 1 protein or any of the functional equivalents of the PRC1 protein.

In the context of the present invention, agents to be identified through the present screening methods may be any compound or composition including several compounds.

Furthermore, the test agent exposed to a cell or protein according to the screening methods of the present invention may be a single compound or a combination of compounds. When a combination of compounds is used in the methods, the compounds may be contacted sequentially or simultaneously.
Any test agent, for example, cell extracts, cell culture supernatant, products of fermenting microorganism, extracts from marine organism, plant extracts, purified or crude proteins, peptides, non-peptide compounds, synthetic micromolecular compounds (including nucleic acid constructs, such as antisense RNA, siRNA, libozymes, etc.) and natural compounds can be used in the screening methods of the present invention. The test agent of the present invention can be also obtained using any of the numerous approaches in combinatorial library methods known in the art, including (1) biological libraries, (2) spatially addressable parallel solid phase or solution phase libraries, (3) synthetic library methods requiring deconvolution, (4) the "one-bead one-compound" library method and (5) synthetic library methods using affinity chromatography selection. The biological library methods using affinity chromatography selection is limited to peptide libraries, while the other four approaches are applicable to peptide, non-peptide oligomer or small molecule libraries of compounds (Lam, Anticancer Drug Des 1997, 12: 145-67). Examples of methods for the synthesis of molecular libraries can be found in the art (DeWitt et al., Proc Natl Acad Sci USA 1993, 90: 6909-13; Erb et al., Proc Natl Acad Sci USA 1994, 91: 11422-6; Zuckermann et al., J Med Chem 37: 2678-85, 1994; Cho et al., Science 1993, 261: 1303-5; Carell et al., Angew Chem Int Ed Engl 1994, 33: 2059; Carell et al., Angew Chem Int Ed Engl 1994, 33: 2061; Gallop et al., J Med Chem 1994, 37: 1233-51). Libraries of compounds may be presented in solution (see Houghten, Bio/Techniques 1992, 13:
412-21) or on beads (Lam, Nature 1991, 354: 82-4), chips (Fodor, Nature 1993, 364: 555-6), bacteria (US Pat. No. 5,223,409), spores (US Pat. No. 5,571,698; 5,403,484, and 5,223,409), plasmids (Cull et al., Proc Natl Acad Sci USA 1992, 89: 1865-9) or phage (Scott and Smith, Science 1990, 249: 386-90; Devlin, Science 1990, 249: 404-6; Cwirla et al., Proc Natl Acad Sci USA 1990, 87: 6378-82; Felici, J Mol Biol 1991, 222: 301-10; US Pat.
Application 2002103360).

A compound in which a part of the structure of the compound screened by any of the present screening methods is converted by addition, deletion and/or replacement, is included in the agents obtained by the screening methods of the present invention.
Furthermore, when the screened test agent is a protein, for obtaining a DNA

encoding the protein, either the whole amino acid sequence of the protein may be determined to deduce the nucleic acid sequence coding for the protein, or partial amino acid sequence of the obtained protein may be analyzed to prepare an oligo DNA as a probe based on the sequence, and screen cDNA libraries with the probe to obtain a DNA encoding the protein.
The obtained DNA is confirmed it's usefulness in preparing the test agent which is a candidate for treating or preventing cancer.
Test agents useful in the screenings described herein can also be antibodies that specifically bind to the MPHOSPHI or PRC 1 protein or partial peptides thereof that lack the biological activity of the original proteins in vivo. For example, antibodies (e.g., monoclonal antibodies) can be tested for their ability to block the binding between the MPHOSPHI and PRC 1 proteins.
As used herein, the term "antibody" refers to an immunoglobulin molecule having a specific structure, that interacts (i.e., binds) only with the antigen that was used for synthesizing the antibody or with an antigen closely related thereto.
Furthermore, an-antibody may be a fragment of an antibody or a modified antibody, so long as it binds to the proteins encoded by the MPHOSPHI or PRCI gene. For instance, the antibody fragment may be Fab, F(ab')2, Fv, or single chain Fv (scFv), in which Fv fragments from H and L
chains are ligated by an appropriate linker (Huston JS et al., Proc Natl Acad Sci USA 1988, 85: 5879-83). More specifically, an antibody fragment may be generated by treating an antibody with an enzyme, such as papain or pepsin. Alternatively, a gene encoding the antibody fragment may be constructed, inserted into an expression vector, and expressed in an appropriate host cell (see, for example, Co MS et al., J Immunol 1994, 152:
2968-76;
Better M & Horwitz AH, Methods Enzymol 1989, 178: 476-96; Pluckthun A & Skerra A, Methods Enzymol 1989, 178: 497-515; Lamoyi E, Methods Enzymol 1986, 121: 652-63;
Rousseaux J et al., Methods Enzymol 1986, 121:663-9; Bird RE & Walker BW, Trends Biotechnol. 1991, 9:132-7).
An antibody may be modified by conjugation with a variety of molecules, such as polyethylene glycol (PEG). Such modified antibodies can also be used in the context of the present invention. The modified antibody can be obtained by chemically modifying an antibody. Such modification methods are conventional in the field.
Alternatively, an antibody may take the form of a chimeric antibody having a variable region derived from a nonhuman antibody and a constant region derived from a human antibody, or a humanized antibody, having a complementarity determining region (CDR) derived from a nonhuman antibody, the frame work region (FR) derived from a human antibody and the constant region. Such antibodies can be prepared by using known technologies.
Humanization can be performed by substituting rodent CDRs or CDR sequences for the corresponding sequences of a human antibody (see e.g., Verhoeyen et al., Science 1988, 239:
1534-6).
Accordingly, such humanized antibodies are chimeric antibodies, wherein substantially less than an intact human variable domain has been substituted by the corresponding sequence from a non-human species.
Fully human antibodies composed of human variable regions in addition to human framework and constant regions can also be used. Such antibodies can be produced using various techniques known in the art. For example in vitro methods involve use of recombinant libraries of human antibody fragments displayed on bacteriophage (e.g., Hoogenboom & Winter, J Mol Biol 1991, 227: 381-8). Similarly, human antibodies can be made by introducing of human immunoglobulin loci into transgenic animals, e.g., mice in which the endogenous immunoglobulin genes have been partially or completely inactivated.
This approach is described, e.g., in U.S. Patent Nos. 6,150,584, 5,545,807;
5,545,806;
5,569,825; 5,625,126; 5,633,425; 5,661,016.
Although the construction of test agent libraries is well known in the art, herein below, additional guidance in identifying test agents and construction libraries of such agents for the present screening methods are provided.
(i) Molecular modeling Construction of test agent libraries is facilitated by knowledge of the molecular structure of compounds known to have the properties sought, and/or the molecular structure of the target molecules to be inhibited, i.e., MPHOSPHI and PRC1. One approach to preliminary screening of test agents suitable for further evaluation is computer modeling of the interaction between the test agent and its target. In the present invention, modeling the interaction between MPHOSPHI and/or PRC 1 provides insight into both the details of the interaction itself, and suggests possible strategies for disrupting the interaction, including potential molecular inhibitors of the interaction.
Computer modeling technology allows the visualization of the three-dimensional atomic structure of a selected molecule and the rational design of new compounds that will interact with the molecule. The three-dimensional construct typically depends on data from x-ray crystallographic analysis or NMR imaging of the selected molecule. The molecular dynamics require force field data. The computer graphics systems enable prediction of how a new compound will link to the target molecule and allow experimental manipulation of the structures of the compound and target molecule to perfect binding specificity.
Prediction of what the molecule-compound interaction will be when small changes are made in one or both requires molecular mechanics software and computationally intensive computers, usually coupled with user-friendly, menu-driven interfaces between the molecular design program and the user.
An example of the molecular modeling system described generally above includes the CHARMm and QUANTA programs, Polygen Corporation, Waltham, Mass. CHARMm performs the energy minimization and molecular dynamics functions. QUANTA
performs the construction, graphic modeling and analysis of molecular structure. QUANTA
allows interactive construction, modification, visualization, and analysis of the behavior of molecules with each other.
A number of articles review computer modeling of drugs interactive with specific proteins, such as Rotivinen et al. Acta Pharmaceutica Fennica 1988, 97: 159-66; Ripka, New Scientist 1988, 54-8; McKinlay & Rossmann, Annu Rev Pharmacol Toxiciol 1989, 29:
111-22; Perry & Davies, Prog Clin Biol Res 1989, 291: 189-93; Lewis & Dean, Proc R Soc Lond 1989, 236: 125-40, 141-62; and, with respect to a model receptor for nucleic acid components, Askew et al., JAm Chem Soc 1989, 111: 1082-90.
Other computer programs that screen and graphically depict chemicals are available from companies such as BioDesign, Inc., Pasadena, Calif., Allelix, Inc, Mississauga, Ontario, Canada, and Hypercube, Inc., Cambridge, Ontario. See, e.g., DesJarlais et al., J Med Chem 1988, 31: 722-9; Meng et al., J Computer Chem 1992, 13: 505-24; Meng et al., Proteins 1993, 17: 266-78; Shoichet et al., Science 1993, 259: 1445-50.
Once a putative inhibitor of the interaction between MPHOSPHI and PRCI has been identified, combinatorial chemistry techniques can be employed to construct any number of variants based on the chemical structure of the identified putative inhibitor, as detailed below. The resulting library of putative inhibitors, or "test agents"
may be screened using the methods of the present invention to identify test agents of the library that disrupt the association of MPHOSPHI and PRC 1.
(ii) Combinatorial chemical synthesis Combinatorial libraries of test agents may be produced as part of a rational drug design program involving knowledge of core structures existing in known inhibitors of the interaction between MPHOSPHI and PRC1. This approach allows the library to be maintained at a reasonable size, facilitating high throughput screening.
Alternatively, simple, particularly short, polymeric molecular libraries may be constructed by simply synthesizing all permutations of the molecular family making up the library. An example of this latter approach would be a library of all peptides six amino acids in length. Such a peptide library could include every 6 amino acid sequence permutation. This type of library is termed a linear combinatorial chemical library.
Preparation of combinatorial chemical libraries is well known to those of skill in the art, and may be generated by either chemical or biological synthesis.
Combinatorial chemical libraries include, but are not limited to, peptide libraries (see, e.g., US Patent 5,010,175; Furka, Int JPept Prot Res 1991, 37: 487-93; Houghten et al., Nature 1991, 354:
84-6). Other chemistries for generating chemical diversity libraries can also be used. Such chemistries include, but are not limited to: peptides (e.g., PCT Publication No. WO
91/19735), encoded peptides (e.g., WO 93/20242), random bio-oligomers (e.g., WO
92/00091), benzodiazepines (e.g., US Patent 5,288,514), diversomers such as hydantoins, benzodiazepines and dipeptides (DeWitt et al., Proc Natl Acad Sci USA 1993, 90:6909-13), vinylogous polypeptides (Hagihara et al., JAmer Chem Soc 1992, 114: 6568), nonpeptidal peptidomimetics with glucose scaffolding (Hirschmann et al., JAmer Chem Soc 1992, 114:
9217-8), analogous organic syntheses of small compound libraries (Chen et al., J. Amer Chem Soc 1994, 116: 2661), oligocarbamates (Cho et al., Science 1993, 261:
1303), and/or peptidylphosphonates (Campbell et al., J Org Chem 1994, 59: 658), nucleic acid libraries (see Ausubel, Current Protocols in Molecular Biology 1995 supplement; Sambrook et al., Molecular Cloning: A Laboratory Manual, 1989, Cold Spring Harbor Laboratory, New York, USA), peptide nucleic acid libraries (see, e.g., US Patent 5,539,083), antibody libraries (see, e.g., Vaughan et al., Nature Biotechnology 1996, 14(3):309-14 and PCT/US96/10287), carbohydrate libraries (see, e.g., Liang et al., Science 1996, 274: 1520-22;
US Patent 5,593,853), and small organic molecule libraries (see, e.g., benzodiazepines, Gordon EM.
Curr Opin Biotechnol. 1995 Dec 1;6(6):624-31.; isoprenoids, US Patent 5,569,588;
thiazolidinones and metathiazanones, US Patent 5,549,974; pyrrolidines, US
Patents 51525,735 and 5,519,134; morpholino compounds, US Patent 5,506,337;
benzodiazepines, 5,288,514, and the like).
(iii) Phage display Another approach uses recombinant bacteriophage to produce libraries. Using the "phage method" (Scott & Smith, Science 1990, 249: 386-90; Cwirla et al., Proc Natl Acad Sci USA 1990, 87: 6378-82; Devlin et al., Science 1990, 249: 404-6), very large libraries can be constructed (e.g., 106 -10g chemical entities). A second approach uses primarily chemical methods, of which the Geysen method (Geysen et al., Molecular Imnnrnology 1986, 23: 709-15; Geysen et al., JlmnaunologicMethod 1987, 102: 259-74); and the method of Fodor et al.
(Science 1991, 251: 767-73) are examples. Furka et al. (14th International Congress of Biochemistry 1988, Volume #5, Abstract FR:013; Furka, Int JPeptide Protein Res 1991, 37:
487-93), Houghten (US Patent 4,631,211) and Rutter et al. (US Patent 5,010,175) describe methods to produce a mixture of peptides that can be tested as agonists or antagonists.

Devices for the preparation of combinatorial libraries are commercially available (see, e.g., 357 MPS, 390 MPS, Advanced Chem Tech, Louisville KY, Symphony, Rainin, Woburn, MA, 433A Applied Biosystems, Foster City, CA, 9050 Plus, Millipore, Bedford, MA). In addition, numerous combinatorial libraries are themselves commercially available (see, e.g., ComGenex, Princeton, N.J., Tripos, Inc., St. Louis, MO, 3D Pharmaceuticals, Exton, PA, Martek Biosciences, Columbia, MD, etc.).

The present invention provides a method of screening for an agent that inhibits the binding between MPHOSPHI and PRC1. An agent that inhibits the binding between MPHOSPHI and PRC 1 is expected to suppress the proliferation of bladder cancer cells, and thus is useful for treating or preventing bladder cancer. Therefore, the present invention also provides a method for screening an agent that suppresses the proliferation of bladder cancer cells, and a method for screening an agent for treating or preventing bladder cancer.
More specifically, the method includes the steps of:
(a) contacting a MPHOSPHI protein with a PRCI protein in the presence of an agent;
(b) detecting the level of binding between the MPHOSPHI and PRC 1 proteins;
(c) comparing the binding level of the MPHOSPHI and PRC1 proteins with that detected in the absence of the agent; and (d) selecting the agent that reduces the binding level of MPHOSPHI and PRCI
proteins as an agent that inhibits the binding between the MPHOSPHI and PRCI
proteins, i.e., an agent that may be used to suppress the proliferation of bladder cancer cells and for treating or preventing bladder cancer.
In the context of the present invention, "inhibition of binding" between two proteins refers to at least reducing binding between the proteins. Thus, in some cases, the percentage of binding pairs in a sample will be decreased compared to an appropriate (e.g., not treated with test compound or from a non-cancer sample, or from a cancer sample) control. The reduction in the amount of proteins bound may be, e.g., less than 90%, 80%, 70%, 60%, 50%, 40%, 25%, 10%, 5%, 1% or less (e.g., 0%), than the pairs bound in a control sample.
Herein, the MPHOSPHI protein and PRC1 protein may include functional equivalents of these proteins as described above. The MPHOSPHI or PRC 1 protein or functional equivalents thereof used in the screening can be prepared as a recombinant protein or natural protein, by methods well known to those skilled in the art. The proteins may be obtained adopting any known genetic engineering methods for producing polypeptides (e.g., Morrison J., J Bacteriology 1977, 132: 349-5 1; Clark-Curtiss & Curtiss, Methods in Enzymology (eds. Wu et al.) 1983, 101: 347-62). For example, a recombinant protein can be prepared by inserting a DNA, which encodes the protein (for example, the DNA
having the nucleotide sequence of SEQ ID NO: 1 or 36), into an appropriate expression vector, introducing the vector into an appropriate host cell, obtaining the extract, and purifying the protein by subjecting the extract to chromatography, for example, ion exchange chromatography, reverse phase chromatography, gel filtration, or affinity chromatography utilizing a column to which antibodies against the protein of the present invention is fixed, or by combining more than one of aforementioned columns.
Also, when the protein useful in the context of the present invention is expressed within host cells (for example, animal cells and E. coli) as a fusion protein with glutathione-S-transferase protein or as a reconibinant protein supplemented with multiple histidines, the expressed recombinant protein can be purified using a glutathione column or nickel column.
After purifying the fusion protein, it is also possible to exclude regions other than the objective protein by cutting with thrombin or factor-Xa as required.
A natural protein can be isolated by methods known to a person skilled in the art, for example, by contacting the affinity column, in which antibodies binding to the MPHOSPHI or PRC1 protein described above are bound, with the extract of tissues or cells expressing the protein. The antibodies can be polyclonal antibodies, monoclonal antibodies, or any modified antibodies so long as it binds to the MPHOSPHI or PRC 1 protein.
The MPHOSPHI or PRC1 protein or functional equivalents thereof may also be produced in vitro adopting an in vitro translation system.
Further, partial peptides of the MPHOSPHI and PRC1 proteins may also be used for the invention so long as they retain their binding activity to each other.
Such partial peptides can be produced by genetic engineering, by known methods of peptide synthesis, or by digesting the natural MPHOSPHI or PRC1 protein with an appropriate peptidase. For peptide synthesis, for example, solid phase synthesis or liquid phase synthesis may be used.
Conventional peptide synthesis methods that can be adopted for the synthesis include:
1) Peptide Synthesis, Interscience, New York, 1966;
2) The Proteins, Vol. 2, Academic Press, New York, 1976;
3) Peptide Synthesis (in Japanese), Maruzen Co., 1975;
4) Basics and Experiment of Peptide Synthesis (in Japanese), Maruzen Co., 1985;
5) Development of Pharmaceuticals (second volume) (in Japanese), Vol. 14 (peptide synthesis), Hirokawa, 1991;
6) W099/67288; and 7) Barany G& Merrifield R.B., Peptides Vol. 2, "Solid Phase Peptide Synthesis", Academic Press, New York, 1980, 100-118.
The polypeptides or fragments thereof may be further linked to other substances, so long as the polypeptides and fragments retain their original ability to bind to each other.
Usable substances include: peptides, lipids, sugar and sugar chains, acetyl groups, natural and synthetic polymers, etc. These kinds of modifications may be performed to confer additional functions or to stabilize the polypeptide and fragments.
The NWHOSPH 1 and PRC 1 polypeptides or functional equivalent thereof to be contacted in the presence of a test agent can be, for example, purified polypeptides, soluble proteins, or fusion proteins fused with other polypeptides.
The screening methods of the present invention provide efficient and rapid identification of test agents that have a high probability of interfering with the association of MPHOSPHI with its binding partner PRC1. Generally, any method that determines the ability of a test agent to interfere with such association is suitable for use with the present invention. For example, competitive and non-competitive inhibition assays in an ELISA
format may be utilized. Control experiments should be performed to determine maximal binding capacity of system (e.g., contacting bound MPHOSPHI with PRC1, and determining the amount of protein bound to MPHOSPHI).
As a method for identifying agents that inhibit the binding of the present invention, many methods well known by one skilled in the art can be used. Such identification can be carried out as an in vitro assay system, for example, in a cellular system.
More specifically, first, either MPHOSPHI or its PRC1 partner is bound to a support, and the other protein is contacted together with a test agent thereto. Next, the mixture is incubated, washed and the other protein bound to the support is detected and/or measured.
Example of supports that may be used for binding the proteins include insoluble polysaccharides, such as agarose, cellulose and dextran; and synthetic resins, such as polyacrylamide, polystyrene and silicon; preferably commercially available beads and plates (e.g., multi-well plates, biosensor chip, etc.) prepared from the above materials may be used.
When using beads, they may be filled into a column. Alternatively, the use of magnetic beads is also known in the art, and enables to readily isolate proteins bound on the beads via magnetism.
The binding of a protein to a support may be conducted according to routine methods, such as chemical bonding and physical adsorption. Alternatively, a protein may be bound to a support via antibodies specifically recognizing the protein.
Moreover, binding of a protein to a support can also be conducted by means of interacting molecules, such as the combination of avidin and biotin.
The binding between proteins is carried out in buffer, for example, but are not limited to, phosphate buffer and Tris buffer, as long as the buffer does not inhibit the binding between the proteins.
In the present invention, a biosensor using the surface plasmon resonance phenomenon may be used as a means for detecting or quantifying the bound protein. When such a biosensor is used, the interaction between the proteins can be observed real-time as a surface plasmon resonance signal, using only a minute amount of polypeptide and without labeling (for example, BlAcore, Pharmacia). Therefore, it is possible to evaluate the binding between the MPHOSPHI and PRC1 using a biosensor such as BIAcore.
Alternatively, either MPHOSPHI or PRC 1 may be labeled, and the label of the bound protein may be used to detect or measure the bound protein.
Specifically, after pre-labeling one of the proteins, the labeled protein is contacted with the other protein in the presence of a test compound, and then bound proteins are detected or measured according to the label after washing.

Labeling substances such as radioisotope (e.g , 3K 14C, 32P, 33P335S, 125I1131I) , enzymes (e.g., alkaline phosphatase, horseradish peroxidase, 0-galactosidase, (3-glucosidase), fluorescent substances (e.g., fluorescein isothiocyanate (FITC), fluorescein, Texas red, green fluorescent protein, and rhodamine), magnetic beads (e.g., DYNABEADSTM), calorimetric labels (e.g., colloidal gold or colored glass or plastic (e.g., polystyrene, polypropylene, latex, etc.) beads), and biotin/avidin, may be used for the labeling of a protein in the present method. Patents teaching the use of such labels include US Patent Nos.
3,817,837;
3,850,752; 3,939,350; 3,996,345; 4,277,437; 4,275,149; and 4,366,241. However, the present invention is not restricted thereto and any label detectable by spectroscopic, photochemical, biochemical, immunochemical, electrical, optical or chemical means may be used.
When the protein is labeled with radioisotope, the detection or measurement can be carried out by liquid scintillation. Alternatively, proteins labeled with enzymes can be detected or measured by adding a substrate of the enzyme to detect the enzymatic change of the substrate, such as generation of color, with absorptiometer. Further, in case where a fluorescent substance is used as the label, the bound protein may be detected or measured using fluorophotometer.
Furthermore, the binding in the present screening method can be also detected or measured using an antibody against MPHOSPHI or PRC1. For example, after contacting MPHOSPHI immobilized on a support with a test agent and PRC1, the mixture is incubated and washed, and detection or measurement can be conducted using an antibody against PRC1. Alternatively, PRCI may be immobilized on a support, and an antibody against MPHOSPHI may be used as the antibody.
When using an antibody in the present screening, the antibody is preferably labeled with one of the labeling substances mentioned above, and detected or measured based on the labeling substance. Alternatively, the antibody against the MPHOSPHI or PRC1 may be used as a primary antibody to be detected with a secondary antibody that is labeled with a labeling substance. Furthermore, the antibody bound to the protein in the screening of the present invention may be detected or measured using protein G or protein A
column.
Alternatively, in another embodiment of the identification method of the present invention, a two-hybrid system utilizing cells may be used ("MATCHMAKER Two-Hybrid system", "Mammalian MATCHMAKER Two-Hybrid Assay Kit", "MATCHMAKER one-Hybrid system" (Clontech); "HybriZAP Two-Hybrid Vector System" (Stratagene);
the references "Dalton and Treisman, Cell 1992, 68: 597-612", "Fields and Sternglanz, Trends Genet 1994, 10: 286-92"). In the two-hybrid system, for example, MPHOSPHI is fused to the SRF-binding region or GAL4-binding region and expressed in yeast cells.
PRC 1 is fused to the VP16 or GAL4 transcriptional activation region and also expressed in the yeast cells in the existence of a test agent. Alternatively, PRC 1 may be fused to the SRF-binding region or GAL4-binding region, and NWHOSPHI to the VP16 or GAL4 transcriptional activation region. When the test agent does not inhibit the binding between MPHOSPHI and PRC1, the binding of the two activates a reporter gene, making positive clones detectable. As a reporter gene, for example, Ade2 gene, lacZ gene, CAT gene, luciferase gene and such can be used besides HIS3 gene.
Herein, the binding level between MPHOSPHI and PRC1 can be also measured as any change occurring after the binding of NWHOSPHI and PRCI. Specifically, such screening can be performed by contacting a test agent with a cell that expresses NWHOSPHI
and PRC1, such as J82 or UMUC cells. For example, the, suppression of cell proliferation may be detected to determine the influence of a test agent on the binding of MPHOSPHI and PRC 1.

1. Competitive assay format Competitive assays may be used for screening test agents of the present invention.
By way of example, a competitive ELISA format may include NWHOSPHI (or PRC1) bound to a solid support. The bound MPHOSPH 1(or PRC 1) would be incubated with PRC 1 (or MPHOSPH1) and a test agent. After sufficient time to allow the test agent and/or PRC1 (or MPHOSPH1) to bind MPHOSPHI (or PRC1), the substrate would be washed to remove unbound material. The amount of PRC 1 bound to NWHOSPHI is then determined.
This may be accomplished in any of a variety of ways known in the art, for example, by using PRC1 (or MPHOSPHI) species tagged with a detectable label, or by contacting the washed substrate with a labeled antibody against PRC 1(or MPHOSPHI). The amount of PRC 1(or MPHOSPH1) bound to MPHOSPHI (or PRCI) will be inversely proportional to the ability of the test agent to interfere with the association of MPHOSPHI to PRC 1.
Protein, including but not limited to, antibody, labeling is described in Harlow &
Lane, Antibodies, A
Laboratory Manual (1988).
In a variation, MPHOSPHI (or PRC1) is labeled with an affinity tag. Labeled MPHOSPH 1(or PRC 1) is then incubated with a test agent and PRC 1(or MPHO SPH
1), then immunoprecipitated. The immunoprecipitate is then subjected to Western blotting using an antibody against PRC1 (or MPHOSPH1). As with the previous competitive assay format, the amount of PRC1 (or MPHOSPHI) found associated with NWHOSPHI (or PRC1) is inversely proportional to the ability of the test agent to interfere with the association of MPHO SPH I and PRC 1.

2. Non-competitive assay format Non-competitive binding assays may also find utility as an initial screen for testing agent libraries constructed in a format that is not readily amenable to screening using competitive assays, such as those described herein. An example of such a library is a phage display library (see, e.g., Barrett et al., Anal Biochem 1992, 204: 357-64).
Phage libraries find utility in being able to produce quickly working quantities of large numbers of different recombinant peptides. Phage libraries do not lend themselves to competitive assays of the invention, but can be efficiently screened in a non-competitive format to determine which recombinant peptide test agents bind MPHOSPHI or PRC
1. Test agents identified as binding can then be produced and screened using a competitive assay format. Production and screening of phage and cell display libraries is well-known in the art and discussed in, for example, Ladner et al., WO 88/06630; Fuchs et al., Biotechnology 1991, 9: 1369-72; Goward et al., TIBS 1993, 18: 136-40; Charbit et al., EMBO J
1986, 5:
3029-37; Cull et al., PNAS USA 1992, 89: 1865-9; Cwirla et al., PNAS USA 1990, 87:
6378-82.
An exemplary non-competitive assay would follow an analogous procedure to the one described for the competitive assay, without the addition of one of the components (MPHOSPHI or PRC1). However, as non-competitive formats determine test agents binding to MPHOSPHI or PRC1, the ability of test agent to bind both MPHOSPHI
and PRC 1 needs to be determined for each candidate. Thus, by way of example, binding of the test agent to immobilized MPHOSPHI may be determined by washing away unbound test agent; eluting bound test agent from the support, followed by analysis of the eluate; e.g., by mass spectroscopy, protein determination (Bradford or Lowry assay, or Abs. at 280nm determination.). Alternatively, the elution step may be eliminated and binding of test agent determined by monitoring changes in the spectroscopic properties of the organic layer at the support surface. Methods for monitoring spectroscopic properties of surfaces include, but are not limited to, absorbance, reflectance, transmittance, birefringence, refractive index, diffraction, surface plasmon resonance, ellipsometry, resonant mirror techniques, grating coupled waveguide techniques and multipolar resonance spectroscopy, all of which are known to those of skill in the art. A labeled test agent may also be used in the assay to eliminate need for an elution step. In this instance, the amount of label associated with the support after washing away unbound material is directly proportional to test agent binding.

A number of well-known robotic systems have been developed for solution phase chemistries. These systems include automated workstations like the automated synthesis apparatus developed by Takeda Chemical Industries, LTD. (Osaka, Japan) and many robotic systems utilizing robotic arms (Zymate II, Zymark Corporation, Hopkinton, Mass.; Orca, Hewlett Packard, Palo Alto, Calif.), which mimic the manual synthetic operations performed by a chemist. Any of the above devices are suitable for use with the present invention. The nature and implementation of modifications to these devices (if any) so that they can operate as discussed herein will be apparent to persons skilled in the relevant art.
In addition, numerous combinatorial libraries are themselves commercially available (see, e.g., ComGenex, Princeton, N.J., Asinex, Moscow, Ru, Tripos, Inc., St. Louis, MO, ChemStar, Ltd, Moscow, RU, 3D Pharmaceuticals, Exton, PA, Martek Biosciences, Columbia, MD, etc.).
According to an aspect of the present invention, the components necessary for the present screening methods may be provided as a kit for screening agents that inhibit the binding between MPHOSPHI and PRCI, or agents that suppress proliferation of bladder cancer cells, or agents for treating or preventing bladder cancer. The kit may contain, for example, the MPHOSPHI polypeptide or a function equivalent thereof, and/or polypeptide or a functional equivalent thereof. Further, the kit may include control reagents (positive and/or negative), detectable labels, reaction buffers, cell culture medium, containers required for the screening, instructions (e.g., written, tape, VCR, CD-ROM, etc.) for carrying out the method, and so on. The components and reagents may be packaged in separate containers.
An agent isolated by any of the methods of the invention can be administered as a pharmaceutical or can be used for the manufacture of pharmaceutical (therapeutic or prophylactic) compositions for humans and other mammals, such as mice, rats, guinea-pigs, rabbits, cats, dogs, sheep, pigs, cattle, monkeys, baboons, and chimpanzees for treating or preventing bladder cancer.
Herein, the term "preventing" means that the agent is administered prophylactically to retard or suppress the forming of tumor or retards, suppresses, or alleviates at least one clinical symptom of cancer. Assessment of the state of tumor in a subject can be made using standard clinical protocols. Prophylactic administration may occur prior to the manifestation of overt clinical symptoms of disease, such that a disease or disorder is prevented or, alternatively, delayed in its progression. In the context of the present invention, "prevention"
encompasses any activity which reduces the burden of mortality or morbidity from disease.

Prevention can occur at primary, secondary and tertiary prevention levels.
While primary prevention avoids the development of a disease, secondary and tertiary levels of prevention encompass activities aimed at preventing the progression of a disease and the emergence of symptoms as well as reducing the negative impact of an already established disease by restoring function and reducing disease-related complications. Accordingly, the present invention encompasses a wide range of prophylactic therapies aimed at alleviating the severity of cancer, particularly bladder cancer.
The isolated agents can be directly administered or can be formulated into dosage form using known pharmaceutical preparation methods. Pharmaceutical formulations may include those suitable for oral, rectal, nasal, topical (including buccal and sub-lingual), vaginal or parenteral (including intramuscular, sub-cutaneous and intravenous) administration, or for administration by inhalation or insufflation. For example, according to the need, the agents can be taken orally, as sugar-coated tablets, capsules, elixirs and microcapsules; or non-orally, in the form of injections of sterile solutions or suspensions with water or any other pharmaceutically acceptable liquid. For example, the agents can be mixed with pharmaceutically acceptable carriers or media, specifically, sterilized water, physiological saline, plant-oils, emulsifiers, suspending agents, surfactants, stabilizers, flavoring agents, excipients, vehicles, preservatives, binders, and such, in a unit dose form required for generally accepted drug implementation. The amount of active ingredients in these preparations makes a suitable dosage within the indicated range acquirable.
Examples of additives that can be mixed to tablets and capsules are, binders such as gelatin, corn starch, tragacanth gum and arabic gum; excipients such as crystalline cellulose;
swelling agents such as corn starch, gelatin and alginic acid; lubricants such as magnesium stearate; sweeteners such as sucrose, lactose or saccharin; and flavoring agents such as peppermint, Gaultheria adenothrix oil and cherry. When the unit-dose form is a capsule, a liquid carrier, such as an oil, can also be further included in the above ingredients. Sterile composites for injections can be formulated following normal drug implementations using vehicles such as distilled water used for injections.
Physiological saline, glucose, and other isotonic liquids including adjuvants, such as D-sorbitol, D-mannose, D-mannitol, and sodium chloride, can be used as aqueous solutions for injections. These can be used in conjunction with suitable solubilizers, such as alcohol, specifically ethanol, polyalcohols such as propylene glycol and polyethylene glycol, non-ionic surfactants, such as Polysorbate 80 (TM) and HCO-50.

Sesame oil or Soy-bean oil can be used as a oleaginous liquid and may be used in conjunction with benzyl benzoate or benzyl alcohol as a solubilizer and may be formulated with a buffer, such as phosphate buffer and sodium acetate buffer; a pain-killer, such as procaine hydrochloride; a stabilizer, such as benzyl alcohol and phenol; and an anti-oxidant.
The prepared injection may be filled into a suitable ampule.
Pharmaceutical formulations suitable for oral administration may conveniently be presented as discrete units, such as capsules, cachets or tablets, each containing a predetermined amount of the active ingredient; as a powder or granules; or as a solution, a suspension or as an emulsion. The active ingredient may also be presented as a bolus electuary or paste, and be in a pure form, i.e., without a carrier. Tablets and capsules for oral administration may contain conventional excipients such as binding agents, fillers, lubricants, disintegrant or wetting agents. A tablet may be made by compression or molding, optionally with one or more formulational ingredients. Compressed tablets may be prepared by compressing in a suitable machine the active ingredients in a free-flowing form such as a powder or granules, optionally mixed with a binder, lubricant, inert diluent, lubricating, surface active or dispersing agent. Molded tablets may be made by molding in a suitable machine a mixture of the powdered compound moistened with an inert liquid diluent. The tablets may be coated according to methods well known in the art. Oral fluid preparations may be in the form of, for example, aqueous or oily suspensions, solutions, emulsions, syrups or elixirs, or may be presented as a dry product for constitution with water or other suitable vehicle before use. Such liquid preparations may contain conventional additives such as suspending agents, emulsifying agents, non-aqueous vehicles (which may include edible oils), or preservatives. The tablets may optionally be formulated so as to provide slow or controlled release of the active ingredient therein.
Formulations for parenteral administration include aqueous and non-aqueous sterile injection solutions which may contain anti-oxidants, buffers, bacteriostats and solutes which render the formulation isotonic with the blood of the intended recipient; and aqueous and non-aqueous sterile suspensions which may include suspending agents and thickening agents.
The formulations may be presented in unit dose or multi-dose containers, for example sealed ampoules and vials, and may be stored in a freeze-dried (lyophilized) condition requiring only the addition of the sterile liquid carrier, for example, saline, water-for-injection, immediately prior to use. Alternatively, the formulations may be presented for continuous infusion. Extemporaneous injection solutions and suspensions may be prepared from sterile powders, granules and tablets of the kind previously described.
Formulations for rectal administration may be presented as a suppository with the usual carriers such as cocoa butter or polyethylene glycol. Formulations for topical administration in the mouth, for example buccally or sublingually, include lozenges, containing the active ingredient in a flavored base such as sucrose and acacia or tragacanth, and pastilles containing the active ingredient in a base such as gelatin and glycerin or sucrose and acacia. For intra-nasal administration the compounds obtained by the invention may be `
used as a liquid spray or dispersible powder or in the form of drops. Drops may be formulated with an aqueous or non-aqueous base, and may include one or more dispersing agents, solubilizing agents or suspending agents. Liquid sprays are conveniently delivered from pressurized packs.
For administration by inhalation the compounds are conveniently delivered from an insufflator, nebulizer, pressurized packs or other convenient means of delivering an aerosol spray. Pressurized packs may include a suitable propellant such as dichlorodifluoromethane, trichlorofluoromethane, dichlorotetrafluoroethane, carbon dioxide or other suitable gas. In the case of a pressurized aerosol, the dosage unit may be determined by providing a valve to deliver a metered amount.
Alternatively, for administration by inhalation or insufflation, the compounds may take the form of a dry powder composition, for example a powder mix of the compound and a suitable powder base such as lactose or starch. The powder composition may be presented in unit dosage form, in for example, capsules, cartridges, gelatin or blister packs from which the powder may be administered with the aid of an inhalator or insufflators.
When desired, the above described formulations, adapted to give sustained release of the active ingredient, may be employed. The pharmaceutical compositions may also contain other active ingredients such as antimicrobial agents, immunosuppressants or preservatives.
Preferred unit dosage formulations are those containing an effective dose, as recited below, or an appropriate fraction of the active ingredient.
Methods well known to one skilled in the art may be used to administer an agent screened by the present methods to patients, for example, as intraarterial, intravenous, or percutaneous injections and also as intranasal, intramuscular or oral administrations. The dosage and method of administration vary according to the body-weight and age of a patient and the administration method; however, one skilled in the art can routinely select a suitable method of administration. If said agent is encodable by a DNA, the DNA can be inserted into a vector for gene therapy and the vector administered to a patient to perform the therapy.
The dosage and method of administration vary according to the body-weight, age, and symptoms of the patient but one skilled in the art can suitably select them.
Although the dose of an agents screened by the present methods depends on the symptoms and such, the compositions may be administered at a dose of from about 0.1 to about 250 mg/kg per day. The dose range for adult humans is generally from about 5 mg to about 17.5 g/day, preferably about 5 mg to about 10 g/day, and most preferably about 100 mg to about 3 g/day. Tablets or other unit dosage forms of presentation provided in discrete units may conveniently contain an amount which is effective at such dosage or as a multiple of the same, for instance, units containing about 5 mg to about 500 mg, usually from about 100 mg to about 500 mg.
When administering parenterally, in the form of an injection to a normal adult (weight 60 kg), although there are some differences according to the patient, target organ, symptoms and method of administration, it is convenient to intravenously inject a dose of about 0.01 mg to about 30 mg per day, preferably about 0.1 to about 20 mg per day and more preferably about 0.1 to about 10 mg per day. Also, in the case of other animals too, it is possible to administer an amount converted to 60 kgs of body-weight.
The agents are preferably administered orally or by injection (intravenous or subcutaneous), and the precise amount administered to a subject will be determined under the responsibility of the attendant physician, considering a number of factors, including the age and sex of the subject, the precise disorder being treated, and its severity. Also the route of administration may vary depending upon the condition and its severity.

The agents screened by the present methods further can be used for treating or preventing bladder cancer in a subject. Administration can be prophylactic or therapeutic to a subject at risk of (or susceptible to) a disorder or having a disorder associated with the binding between the MPHOSPHI and PRC1 proteins. The method includes decreasing the binding between MPHOSPHI and PRC1 in bladder cancer cells. The function can be inhibited through the administration of an agent obtained by any of the screening methods of the present invention.

Unless otherwise defined, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention belongs. In case of conflict, the present specification, including definitions, will control.
Hereinafter, the present invention is described in more detail with reference to the Examples. However, the following materials, methods and examples only illustrate aspects of the invention and in no way are intended to limit the scope of the present invention. As such, methods and materials similar or equivalent to those described herein can be used in the practice or testing of the present invention.

EXAMPLE
1. Materials and Methods (1) Bladder cancer cell lines and tissue samples Human bladder cancer cell lines, HT 1197, LTM-UC-3, J82, HT 13 76, SW780 and RT4, were purchased from American Type Culture Collection (ATCC; Rockville, MD). All of the bladder cancer cell lines, COS7 and NIH3T3 cells were grown in monolayer in appropriate medium; i.e. EMEM (Sigma, St. Louis, MO) with 0.1mM essential amino acid (Roche), 1 mM sodium pyruvate (Roche), for HT 1197, UMUC3, J82 and HT 13 76; L-15 for SW 780; McCoy's 5a (Sigma) for RT-4; and Dulbecco's modified Eagle's medium (Invitrogen, Carlsbad, CA) for COS7 and NIH3T3. Each medium was supplemented with 10% fetal bovine serum (Cansera) and 1% antibiotic/antimycotic solution (Sigma). SW780 was maintained at 37 C in atmosphere of humidified air without C02, though the remaining cells were maintained at 37 C in atmosphere of humidified air with 5% COz.
Tissue samples from surgically-resected invasive or superficial bladder cancers, and their corresponding clinical information were obtained after obtaining written informed consent.

(2) Semi-quantitative RT-PCR analysis Total RNAs were extracted from cultured cells and clinical tissues using RNeasy Micro Kits (Qiagen, Valencia, CA). Extracted RNAs and normal human tissue polyA+ RNAs were treated with DNase I (Nippon Gene, Tokyo, Japan), and reversely transcribed using oligo (dT) primer and SuperScript II reverse transcriptase (Invitrogen, Carlsbad, CA). Semi-quantitative reverse transcription-PCR (RT-PCR) experiments were carried out with the following MPHOSPHl-specific primers or with GAPDH-specific primers as internal control:
MPHOSPHI, 5'-CCGGGAAAGTAAACTGACTCAC-3' (SEQ ID NO: 3) and 5'-TTCTAGCTCCTCAACCAAATCCT-3' (SEQ ID NO: 4); and GAPDH, 5'-CGACCACTTTGTCAAGCTCA-3' (SEQ ID NO: 5) and 5'-GGTTGAGCACAGGGTACTTTATT-3' (SEQ ID NO: 6).
PCR reactions were optimized for the number of cycles to ensure product intensity within the logarithmic phase of amplification.

(3) Northern blot analysis Human multiple-tissue blots (Takara Clontech, Palo Alto, CA), and bladder cancer cell blots composed of mRNAs from 6 bladder cancer cell lines and 8 normal human organs were hybridized with 32P-labeled MPHOSPHI cDNA. The probe, MPHOSPHI cDNA, was prepared by RT-PCR using primers 5'-TGCTGGTTCAGAACGAACTATG-3' (SEQ ID NO:
7) and 5'-TCCTCGTGGCTAATGAAAGC-3' (SEQ ID NO: 8). Prehybridization, hybridization, and washing were performed according to the supplier's recommendations.
The blots were autoradiographed with intensifying screens at -80 C for 14 days.

(4) Expression vector construction Open reading frame sequences ofMPHOSPHI and PRCI were obtained by PCR
using KOD-Plus DNA polymerase (Toyobo, Osaka, Japan) with following primer sets:
MPHOSPHI, forward:
5'-ATAAGAATGCGGCCGCAATGGAATCTAATTTTAATCAAGAGG-3' (SEQ ID NO: 9), and reverse: 5'-ATAAGAATGCGGCCGCTTTGGCTGTTTTTGTTCGA-3' (SEQ ID NO: 10) (underline indicates NotI restriction enzyme sites); and PRC1, forward: 5'-CCGGAATTCTCCGCCATGAGGAGAAGTGA-3' (SEQ ID NO: 11) (underline indicates EcoRl restriction enzyme sites), and reverse: 5'-TTGCCGCTCGAGGGACTGGATGTTGGTTGAA-3' (SEQ ID NO: 12) (underline indicates Xhol restriction enzyme sites).

The PCR products ofMPHOSPHI and PRCI were inserted into the Notl site of HA-tagged pCAGGS expression vector and .the EcoRl and Xhol site of FLAG-tagged pCAGGS, respectively. DNA sequences of these constructs were confirmed by DNA
sequencing. The primers for amplification of truncated MPHOSPHI sequences were as follows: 1188 to 1302, forward : 5' -ATAAGAATGCGGCCGCTATGGAAATCACACAGTTAACAAATAATTTGC-3' (SEQ ID NO: 13), and reverse: 5'-ATAAGAATGCGGCCGCACCTGAATGGTTCGCTGTTTCAT-3' (SEQ ID NO:
14); and 1295 to 1465, forward: 5'-CCGGAATTCATGAAACAGCGAACCATTCAG-3' (SEQ ID NO: 15), and reverse: 5'-ATAAGAATGCGGCCGCTGTGTCAGTATTTCCATTTCATTCTGTT 3' (SEQ
ID NO: 16); 1456 to 1662, forward: 5'-CCGGAATTCATGAAGCAACAGAATGAAATGGAAATACT-3' (SEQ ID NO:
17), and reverse: 5'-ATAAGAATGCGGCCGCTCTGGACGTATGGCAACCTTTT-3' (SEQ ID NO:
18); 1655 to 1725, forward: 5'-ATAAGAATGCGGCCGCTATGGAACAAAAGGTTGCCATACGTC-3' (SEQ
ID NO: 19), and reverse: 5'-ATAAGAATGCGGCCGCTGTGCTTCTACATTTGAGAGCTTTGA-3' (SEQ ID
NO:20); and 1718 to 1780, forward: 5'-CCGGAATTCATGTCAAAGCTCTCAAATGTAGAAGCA-3' (SEQ ID NO:21), and reverse: 5'-ATAAGAATGCGGCCGCTTTGGCTGTTTTTGTTCGA-3' (SEQ ID NO: 10) (underlines indicate NotI or EcoRI restriction enzyme sites).

(5) Anti-MPHOSPHI-specific polyclonal antibodies Plasmid designed to express a part of MPHOSPHI (1612-1780 a.a.) or PRC1 (234-360 a.a.) with His-tagged epitope at their C-terminus was prepared using pET21 vector (Novagen, Madison, WI). The recombinant peptides were expressed in Escherichia coli BL21 codon-plus strain (Stratagene, La Jolla, CA), respectively, and purified using Ni-NTA
resin agarose (Qiagen) and TALON (Takara Clontech) according to the supplier's protocols.
The purified recombinant proteins were inoculated into rabbits, and the immune sera were purified on affinity columns according to standard methodology. Affinity-purified anti-MPHOSPHI antibodies and anti-PRC1 antibodies were used for Western blotting, immunoprecipitation, and immunocytostaining as described below. These antibodies were confirmed to specifically recognize endogenous MPHOSPHI protein in UMUC3 bladder cancer cells by Western blot analysis.

(6) Synchronization and flow c, ometry analysis Cells were arrested in GI phase 24 hr after transfection with aphidicolin (2 g/ml) for further 16 hr. Cell cycle was released by washing five times with PBS (-).
After release from the cell cycle arrest, cells were collected at indicated time points. For FACS analysis, 400 1 aliquot of synchronized adherent and detached cells were combined and fixed with 70% ethanol at 4 C. After washing with PBS (-), the cells were incubated for 30 min with 1 ml of PB S containing 1 mg of RNase I at 3 7 C. The cells were then stained in 1 ml of PB S
containing 50mg of propidium iodide (PI). The percentages of each fraction of cell cycle phases were counted for at least 10000 cells in a flow cytometer (FACScalibur;
Becton Dickinson, San Diego, CA). For immunocytochemical analysis, synchronized cells were fixed at indicated time points and stained as shown below.
(7) Immunocytochemical analysis UMUC3 cells were seeded at 1x105 cells per well. After 24 hr, the cells were fixed with PBS containing 4% paraformaldehyde, and then rendered permeable with PBS
containing 0.1% Triton X-100 for 2 min at room temperature. Subsequently, the cells were covered with 3% BSA in PBS for 12 hr at 4 C, to block nonspecific antibody-binding sites.
Then, the cells were incubated with affinity-purified anti-MPHOSPHI specific polyclonal antibody diluted 1:100 in the blocking solution. After washing with PBS, the UMUC3 cells were stained with an Alexa488-conjugated anti-rabbit secondary antibody (Molecular Probe) at 1:1000 dilutions. Nuclei were counter-stained with 4', 6'-diamidine-2'-phenylindole dihydrochloride (DAPI). Fluorescent images were obtained under a microscope (Leica, Tokyo, Japan).

(8) Immunohistochemical analysis Conventional paraffin-embedded tissue sections from bladder cancers were obtained from surgical specimens. To investigate the expression of MPHOSPHI
protein in clinical materials, tissue sections were stained using ENVISION+ Kit/HRP
(DakoCytomation, Glostrup, Denmark) after the sections were deparaffinized and autocraved for 15 min at 108 C in antigen retrieval solution high pH (DAKO). After blocking of endogenous peroxidase and proteins, these sections were incubated with anti-MPHOSPHI
polyclonal antibody at 1:80 dilutions. Immunodetection was done with peroxidase-labeled anti-rabbit immunoglobulin (Envision kit, Dako Cytomation, Carpinteria, CA). Finally, the reactants were developed with 3, 3 V-diaminobenzidine (Dako) and the cells were counter-stained with hematoxylin.

(9) Small-interfering RNA assay A vector-based RNA interference (RNAi) system, psiU6BX3.0, had been previously established which system was designed to synthesize small-interfering RNAs (siRNA) in mammalian cells (Shimokawa T et al., Cancer Res 2003, 63: 6116-20).
Plasmids designed to express siRNA were prepared by cloning of double-stranded oligonucleotides into the psiU6BX vector. The siRNA-expression vector was transfected using Lipofectamine2000 (Invitrogen) or FuGENE6 (Roche) into J82 or UMUC cells, respectively, according to the supplier's recommendations. The transfected-cells were cultured for 28 or 21 days in the presence of 0.6 or 1.0 mg/ml of geneticin (G418), respectively, and the numbers of colonies were counted by Giemsa staining. Viability of the cells was evaluated by MTT
assay on day 28 or 14 after the treatment.
To confirm suppression of MPHOSPHI protein expression, Western blot analysis was carried out using affinity-purified anti-MPHOSPHI specific polyclonal antibody and semi-quantitative RT-PCR according to standard protocol. Moreover, the knockdown effect of PRC1-specific siRNAs was confirmed by semi-quantitative RT-PCR using specific primers.
The primers for GAPDH as internal control was the same as above, and PRCI-specific primers were as follows: 5'-GTTTGTCCCTTGGCTCTCATC-3' (SEQ ID NO: 22) and 5'-AGTCCACACTGGTAAGCTTTTGA-3' (SEQ ID NO: 23). The target sequences of the synthetic oligonucleotides for RNAi were as follows: EGFP as a control, 5'-GAAGCAGCACGACTTCTTC-3' (SEQ ID NO:24);
siRNA-MPHOSPHI, 5'-GTGAAGAAGTGCGACCGAA-3' (SEQ ID NO:25);
siRNA-MPHOSPHI mismatch, 5'-TTGTAGAAGTGCGACCGAG-3' (SEQ ID NO:26);
siRNA-PRC.1 #1, 5'-GGAAAGACTCATCAAAAGC-3' (SEQ ID NO:27);
siRNA-PRC1 #2, 5'-GCATATCCGTCTGTCAGAAT-3' (SEQ ID NO:31); and siRNA-PRC1 #2 mismatch, 5'-TCATATCCCTCTGTAAGAT-3' (SEQ ID NO:35).
(10) Establishment of NIH3T3 cells stably expressing MPHOSPHI
MPHOSPHI expression vector or mock vector was transfected into NIH3T3 cells using FUGENE6 as describe above. Transfected cells were incubated in culture medium containing 0.9 mg/ml of geneticin (G418) (Invitrogen). Clonal NIH3T3 cells were subcloned by limiting dilution. Expression of HA-tagged MPHOSPHI was assessed by Western blot analysis using anti-HA monoclonal antibody. Eventually, several clones were established and designated as MPHOSPHI-NIH3T3.

To investigate the growth-promoting effect of MPHOSPHI in vitro, 5000 cells were seeded to three independent MPHOSPHI-NIH3T3 cells and three independent MOCK-NIH3T3 cells, and the numbers of cells were counted by MTT assay everyday for five days.
These experiments were done in triplicate.

In vivo experiments were performed in animal facility in accordance with institutional guidelines. To further examine the effect of MPHOSPHI on tumor growth in nude mice, sixteen BALB/cA Jcl-nu mice (female, 7weeks old) were injected s.c.
with NIH3T3-MPHOSPHI-#1, NIH3T3-MPHOSPHI-#3, NIH3T3-Mock-#1 or NIH3T3-Mock-#3 (5 x 106 cells). Tumors were measured every 3 days for 3 weeks, and their volumes were estimated by following formula: 0.5 x (larger diameter) x (smaller diameter)2 as described previously.

(11, Immunoprecipitation and Western blotting Cells were lysed in lysis buffer (50 mM Tris-HCL (pH 8.0), 150 mM NaCI, 0.5%
NP-40 and Protease Inhibitor Cocktail Set III (Calbiochem, San Diego, CA)).
Equal amounts of total proteins were incubated at 4 C for 2 hr with 2 g of rat anti-HA
(Roche) or mouse anti-c-myc (Sigma) antibody. Immunocomplexes were incubated with protein G-Sepharose (Zymed Laboratories, South San Francisco, CA) for 2 hr and then washed with lysis buffer.
Co-precipitated proteins were separated by SDS-PAGE.

Proteins separated by SDS-PAGE were transferred on nitrocellulose membranes, and then incubated with mouse anti-c-myc (Sigma) or rat anti-HA (Roche) antibody. Then, after incubation with secondary antibody conjugated to HRP, signals were visualized with ECL kit (Amersham Biosciences).

(12) Knockdown effects of MPHOSPHI and PRC 1 on cell growth After UMUC3 cells were transfected with plasmids designed to express si-EGFP
(negative control), si-MPHOSPHI, or si-PRC1 (see the above-mentioned siRNA
assay) using FuGENE6 (Roche), their cellular morphologies were examined for 4 days. On day 4 after the transfection, the cells were immunocytochemically stained with Allexa594 phalloidin (Molecular probes) and DAPI. Fluorescent images were obtained under a confocal microscope (Leica, Tokyo, Japan). To examine the suppressive effect of siRNA
on MPHOSPHI expression, Western blot analysis was carried out using affinity-purified anti-MPHOSPHI antibody according to standard protocol.

2. Results (1) Identification ofMPHOSPHI as an up-regulated gene in bladder cancers To identify molecules that may be applicable as targets for novel therapeutic drugs, genome-wide expression profile analysis on 26 invasive bladder cancer cases were previously performed using cDNA microarray representing 27,648 genes or ESTs (Takata R et al., Clin Cancer Res April 1, 2005,11(7): 2625-36).

Through this analysis, a set of genes whose expression was up-regulated in the majority of examined bladder cancer cells had been identified. Among them, MPHOSPHI
(M-phase phosphoprotein 1) gene, whose up-regulation could be confirmed in clinical bladder cancer cases (Fig. 1A) as well as bladder cancer cell lines (data not shown) by semi-quantitative RT-PCR analysis, but which expression was undetectable in any of examined normal organs except testis, was selected for further investigation.
Subsequent Northern blot analysis confirmed that a transcript of approximately 7 kb ofMPHOSPHI gene was up-regulated in all of the examined 6 bladder cancer cell lines, but not expressed in the examined normal organs except the testis (Fig. 1B, C).

Then, polyclonal antibody against MPHOSPHI was developed to investigate the expression of this protein in bladder cancer tissues (see Materials and Methods).
Immunohistochemical analysis with affinity-purified anti-MPHOSPHI polyclonal antibodies revealed positive staining in the examined bladder cancer cells of clinical invasive bladder cancer tissue sections, while no staining was detected in the examined normal bladder tissues (Fig. 1D). Further, up-regulated expression of MPHOSPHI was detected in the examined bladder cancers at an earlier stage (Fig. 1D), although its up-regulation was initially identified through the expression profile analysis of invasive bladder cancers, which suggests the involvement ofMPHOSPHI in the development, but not in the progression of bladder cancers.
(2) Subcellular localization of MPHOSPHI in bladder cancer cells To further characterize the MPHOSPHl gene, subcellular localization of endogenous MPHOSPHI was examined in UMUC3 bladder cell line by immunocytochemical analysis using anti-MPHOSPHI antibodies. Endogenous MPHOSPHI
was mainly localized in the nucleus in cells at interphase, but was observed allover the cytoplasm in some M-phase cells after the disappearance of nuclear membrane.
Since the immunocytochemical analysis suggested cell-cycle dependent expression pattern of MPHOSPHI, UMUC3 cells were synchronized using aphidicolin to examine the localization of MPHOSPHI at different cell-cycle points. As shown in Fig. 2, endogenous MPHOSPHI
protein was localized in the cytoplasm of prophase, metaphase and early anaphase.
Furthermore, the protein accumulated on the midzone of the cells in late anaphase and finally concentrated at the contractile ring when the cells were at telophase. These findings suggest an important role for MPHOSPHI in cytokinesis.

(3) Oncogenic activity of MPHOSPHI

To assess the oncogenic role ofMPHOSPHI, endogenous expression of MPHOSPHI was knocked down in bladder cancer cell lines, J82 and UMUC3, which cell lines showed high expression levels ofMPHOSPHl, by means of the mammalian vector-based RNA interference (RNAi) technique (see Materials and Methods). The expression levels of MPHOSPHI were examined by semi-quantitative RT-PCR and Western blot analyses to find MPHOSPHI-specific siRNAs (si-MPHOSPHI) to significantly suppress the expression of this gene as compared with a control siRNA-construct (si-EGFP) (Fig. 3A).
Colony-formation and MTT assays using these siRNA constructs (Figs. 3B and 3C) indicated that the introduction of MPHOSPHI-specific siRNA suppressed the growth of J82 and UMUC3 cells. Furthermore, siRNA that contained 3-bp replacement in si-MPHOSPHI
(si-MPHOSPHI-mismatch, see Materials and methods) were constructed and examined, which, in turn, led to the discovery that it had no suppressive effect on the expression of MPHOSPHI or the growth of bladder cancer cells (Fig. 3A).

To further confirm the growth promoting effect ofMPHOSPHI, NIH3 T3 -derivative cells that stably expressed exogenousMPHOSPHI (NIH3T3-MPHOSPHI-1, -2, and -3 cells) were established. The Western-blot analysis indicated high levels of exogenous MPHOSPHI
protein in three derivate clones (Fig. 4A). Subsequent MTT assays showed that three derivative cell lines, NIH3T3-MPHOSPHI-1, -2 and -3, grew much faster than cells transfected with mock plasmid (NIH3T3Mock-1, -2 and -3 cells) (Fig. 4B), indicating MPHOSPHI expression was likely to enhance cell growth. Next, FACS analysis was performed to examine whether NIH3T3-derivative cells that stably expressed exogenous MPHOSPHI enhance the progression of cell cycle. As shown in Fig. 4C, the cell cycle of NIH3T3-MPHOSPHI cells progressed faster than that of NIH3T3-mock cells at all time points, especially in G2/M phase cells (6hr) (MPHOSPHI: mock=35.71%: 22.10%).
Eventually, NIH3T3-mock cells returned to almost the GO/G1 phase at 12 hr, whereas the NIH3T3-MPHOSPHI cells passed over the GO/Gl phase and went into the S phase at 12 hr (Fig. 4C).

To investigate the role ofMPHOSPHl in vivo, either NIH3T3-MPHOSPHI cells or NIH3T3-Mock cells were transplanted into BALB/cA Jcl-nu mice by s.c. (female, 7 weeks old). All of the 12 animals transplanted with either NIH3T3-MPHOSPHI cells (-#1 or -#2) formed significantly faster, and larger tumors in the nude mice as compared with those transplanted with NIH3T3-Mock (-#1 or -#2) cells (Fig. 4D). These findings imply an oncogenic role for MPHOSPHI in the development of bladder cancer both in vivo and in vitro.
(4) Interaction of MPHOSPHI with PRC l To further study the role of MPHOSPHI in bladder cancer cells, MPHOSPHI
interacting proteins were investigated. The search resulted in the identification of protein-regulating cytokinesis 1(PRCI) protein as a possible candidate to interact with MPHOSPH, since this protein is known to localize in the midbody or near the contractile ring in late anaphase or telophase cells, and to function in midzone formation and cytokinesis. In addition, PRC 1 was reported to interact with several kinesin family proteins (Ban R et al., J
Biol Chem 2004, 279: 16394-402; Kurasawa Y et al., EMBO J 2004, 23: 3237-48;
Zhu C &
Jiang W, Proc Natl Acad Sci USA 2005, 102: 343-8; Gruneberg U et al., J Cell Biol 2006, 172: 363-72).

Analysis of the expression pattern of PRC 1 in bladder cancer cases by semi-quantitative RT-PCR analysis led to the discovery that PRCI and MPHOSPHI are co-upregulated in bladder cancer cases (Fig. 5A). Subsequently, co-immunoprecipitation experiments were performed using HA-tagged MPHOSPHI and FLAG-tagged PRC1 that were co-transfected into COS7 cells. Using anti-FLAG or anti-HA antibodies, HA-tagged MPHOSPHI was identified to co-precipitate with FLAG-tagged PRC1 or FLAG-tagged PRCI was identified to reversely co-precipitated with HA-tagged MPHOSPHI as well (Fig.
5B), indicating the interaction of these two proteins. Subsequent immunocytochemical analysis indicated that exogenous PRC 1 localized to stained fiber array filament and co-localized with endogenous MPHOSPHI at interphase of the UMUC cells (Fig. 5C).

In addition, these proteins were further observed to co-localize during M-phase, especially in late anaphase, translocate to the spindle midzone where they co-localize as a series of narrow microtubule-bundle bars at the midozone. However, interestingly, the two proteins were separately localized in telophase cells. PRC1 (red) localized in the center of midbody as described previously, while MPHOSPHI (green) was present near the plus ends of the microtubule. These findings strongly suggest that MPHOSPHI interacts with PRC 1 during cell cycle except during bladder cell telophase.

(5) Determination of interaction of MPHOSPHI with PRC 1 To identify the region ofMPHOSPHI responsible for interaction with PRC1, co-immunoprecipitation experiments were performed using a series of truncated forms of HA-tagged MPHOSPHI and FLAG-tagged full-length PRC1 to be co-transfected into COS7 cells (Fig. 6A). Immunoblotting analysis with anti-FLAG or anti-HA antibodies showed that two constructs (1188-1456 and 1662-1718 amino acids) ofMPHOSPHI bound to PRC1, indicating that MPHOSPHI interacts with PRC1 through two binding regions at the C-terminus of the stalk region and the tail region of MPHOSPHI (Fig. 6B).

(6) Growth-inhibitory effects of PRC 1-specific siRNA in bladder cancer To further validate the biological role of PRC 1 on bladder carcinogenesis, specific siRNA expression vectors were constructed to examine the knockdown effect of each of the constructs in J82 and UMUC3 bladder cancer cell lines, which over-expresses PRC 1.
Semi-quantitative RT-PCR showed that si-PRC 1# 1 and si-PRC 1 #2 have drastic knockdown effects on PRC1 expression, whereas si-PRCl-mismatch construct which contained 3 -bp replacement to si-PRC 1# 1 or a negative control si-EGFP revealed to have no or little knockdown effect. The introduction of si-PRC1#1 and si-PRC1#2 into in J82 and cells resulted in significant decrease in the number of colonies and cell viability, whereas control siRNAs and si-PRCl-mismatch had no or little effect on the colony formation or cell viability (Figs. 7A and 7B). These findings suggest that PRC 1 is also likely to play a crucial role in the growth of bladder cancer cells.

Furthermore, as shown in Fig. 7C, immunocytochemical analysis was performed to examine the knockdown effect of MPHOSPH 1 or PRC 1 on cytokinesis of cancer cells.
MPHOSPHI or PRC1-specific siRNA expression vectors were transfected into UMUC3 cells, respectively, to observe cell morphology during the 4 days after the transfection. Interestingly, formation of multiple nuclei was observed in cells transfected with either of the two siRNAs on day 4 after the transfection (Fig. 7C). The finding indicates that the absence of MPHOSPHI or PRC1 results in cytokinesis failure, which, in turn, results in the formation of multi-nucleated cells that ultimately induce cell death.

INDUSTRIAL APPLICABILITY

The present invention relates to a method for identifying or screening a therapeutic or preventive agent for cancer, in particular, bladder cancer, by detecting compounds that inhibit the binding of the MPHOSPHI protein with the PRC1. According to the present invention, it was shown that cytokinesis failure and formation of multiple nuclei were observed by knockdown of MPHOSPHI or PRC1. Thus, the present screening method might hold promise for development of a new therapeutic strategy for the treatment and prevention of bladder cancer.

The data reported herein add to a comprehensive understanding of bladder cancer, and provide clues for identification of molecular targets for therapeutic drugs and preventive agents. Such information contributes to a more profound understanding of carcinogenesis, and provides indicators for developing novel strategies for treatment and ultimately prevention of bladder cancer.

All patents, patent applications, and publications cited herein are incorporated by reference in their entirety.

Furthermore, while the invention has been described in detail and with reference to specific embodiments thereof, it is to be understood that the foregoing description is exemplary and explanatory in nature and is intended to illustrate the invention and its preferred embodiments. Through routine experimentation, one skilled in the art will readily recognize that various changes and modifications can be made therein without departing from the spirit and scope of the invention. Thus, the invention is intended to be defined not by the above description, but by the following claims and their equivalents.

Claims (6)

1. A method of identifying an agent that inhibits the binding between MPHOSPH1 and PRC1, said method comprising the steps of:
a) contacting a first polypeptide selected from the group consisting of:
i) a polypeptide comprising the amino acid sequence of SEQ ID NO: 2;
ii) a polypeptide comprising the amino acid sequence of SEQ ID NO: 2 wherein one or more amino acids are added, substituted, deleted, or inserted, provided the polypeptide has a binding activity to PRC1 equivalent to that of a polypeptide consisting of the amino acid sequence of SEQ ID NO: 2;
iii) a polypeptide comprising an amino acid sequence that is at least about 80%
homologous to SEQ ID NO: 2, provided the polypeptide has a binding activity to PRC1 equivalent to that of a polypeptide consisting of the amino acid sequence of SEQ ID NO: 2; and vi) a polypeptide encoded by a polynucleotide that hybridizes under stringent conditions to a polynucleotide consisting of the nucleotide sequence of SEQ ID

NO: 1, provided the polypeptide has the binding activity to PRC1 equivalent to that of a polypeptide consisting of the amino acid sequence of SEQ ID NO: 2;
in the presence of an agent with a second polypeptide selected from the group consisting of:
i) a polypeptide comprising the amino acid sequence of SEQ ID NO: 37;
ii) a polypeptide comprising the amino acid sequence of SEQ ID NO: 37 wherein one or more amino acids are added, substituted, deleted, or inserted, provided the polypeptide has a binding activity to MPHOSPH1 equivalent to that of a polypeptide consisting of the amino acid sequence of SEQ ID NO: 37;
iii) a polypeptide comprising the amino acid sequence that has at least about 80%
homology to SEQ ID NO: 37, provided the polypeptide has a binding activity to MPHOSPH1 equivalent to that of a polypeptide consisting of the amino acid sequence of SEQ ID NO: 37; and vi) a polypeptide encoded by a polynucleotide that hybridizes under stringent conditions to a polynucleotide consisting of the nucleotide sequence of SEQ ID

NO: 36, provided the polypeptide has the binding activity to MPHOSPH1 equivalent to that of a polypeptide consisting of the amino acid sequence of SEQ ID NO: 37;

b) detecting the level of binding between the first polypeptide and the second polypeptide;
c) comparing the binding level of the first and second polypeptides with that detected in the absence of the agent; and d) selecting the agent that reduces the binding level between the first and second polypeptides.

2. The method of claim 1, wherein the first polypeptide comprises the amino acid residues from 1188 to 1718 of SEQ ID NO: 2.

3. A method of identifying an agent that suppresses the proliferation of bladder cancer cells, said method comprising the steps of:
a) contacting a first polypeptide selected from the group consisting of:
i) a polypeptide comprising the amino acid sequence of SEQ ID NO: 2;
ii) a polypeptide comprising the amino acid sequence of SEQ ID NO: 2 wherein one or more amino acids are added, substituted, deleted, or inserted, provided the polypeptide has a binding activity to PRC1 equivalent to that of a polypeptide consisting of the amino acid sequence of SEQ ID NO: 2;
iii) a polypeptide comprising the amino acid sequence that has at least about 80%
homology to SEQ ID NO: 2, provided the polypeptide has a binding activity to PRC1 equivalent to that of a polypeptide consisting of the amino acid sequence of SEQ ID NO: 2; and vi) a polypeptide encoded by a polynucleotide that hybridizes under stringent conditions to a polynucleotide consisting of the nucleotide sequence of SEQ ID

NO: 1, provided the polypeptide has a binding activity to PRC1 equivalent to that of a polypeptide consisting of the amino acid sequence of SEQ ID NO: 2;
in the presence of an agent with a second polypeptide selected from the group consisting of:
i) a polypeptide comprising the amino acid sequence of SEQ ID NO: 37;
ii) a polypeptide comprising the amino acid sequence of SEQ ID NO: 37 wherein one or more amino acids are added, substituted, deleted, or inserted, provided the polypeptide has a binding activity to MPHOSPH1 equivalent to that of a polypeptide consisting of the amino acid sequence of SEQ ID NO: 37;
iii) a polypeptide comprising the amino acid sequence that has at least about 80%
homology to SEQ ID NO: 37, provided the polypeptide has a binding activity to MPHOSPH1 equivalent to that of a polypeptide consisting of the amino acid sequence of SEQ ID NO: 37; and vi) a polypeptide encoded by a polynucleotide that hybridizes under stringent conditions to a polynucleotide consisting of the nucleotide sequence of SEQ ID

NO: 36, provided the polypeptide has a binding activity to MPHOSPH1 equivalent to that of a polypeptide consisting of the amino acid sequence of SEQ ID NO: 37;
b) detecting the level of binding between the first and the second polypeptides;
c) comparing the binding level of the first and second polypeptides with that detected in the absence of the agent; and d) selecting the agent that reduces the binding level between the first and second polypeptide as an agent that suppresses the proliferation of bladder cancer cells.

4. The method of claim 3, wherein the first polypeptide comprises the amino acid residues from 1188 to 1718 of SEQ ID NO: 2.

5. A method of identifying an agent for treating or preventing bladder cancer, said method comprising the steps of:
a) contacting a first polypeptide selected from the group consisting of:
i) a polypeptide comprising the amino acid sequence of SEQ ID NO: 2;
ii) a polypeptide comprising the amino acid sequence of SEQ ID NO: 2 wherein one or more amino acids are added, substituted, deleted, or inserted, provided the polypeptide has a binding activity to PRC1 equivalent to that of a polypeptide consisting of the amino acid sequence of SEQ ID NO: 2;
iii) a polypeptide comprising the amino acid sequence that has at least about 80%
homology to SEQ ID NO: 2, provided the polypeptide has a binding activity to PRC1 equivalent to that of a polypeptide consisting of the amino acid sequence of SEQ ID NO: 2; and vi) a polypeptide encoded by a polynucleotide that hybridizes under stringent conditions to a polynucleotide consisting of the nucleotide sequence of SEQ ID

NO: 1, provided the polypeptide has a binding activity to PRC1 equivalent to that of a polypeptide consisting of the amino acid sequence of SEQ ID NO: 2;
in the presence of an agent with a second polypeptide selected from the group consisting of:

i) a polypeptide comprising the amino acid sequence of SEQ ID NO: 37;
ii) a polypeptide comprising the amino acid sequence of SEQ ID NO: 37 wherein one or more amino acids are added, substituted, deleted, or inserted, provided the polypeptide has a binding activity to MPHOSPH1 equivalent to that of a polypeptide consisting of the amino acid sequence of SEQ ID NO: 37;
iii) a polypeptide comprising the amino acid sequence that has at least about 80%
homology to SEQ ID NO: 37, provided the polypeptide has a binding activity to MPHOSPH1 equivalent to that of a polypeptide consisting of the amino acid sequence of SEQ ID NO: 37; and vi) a polypeptide encoded by a polynucleotide that hybridizes under stringent conditions to a polynucleotide consisting of the nucleotide sequence of SEQ ID

NO: 36, provided the polypeptide has a binding activity to MPHOSPH1 equivalent to that of a polypeptide consisting of the amino acid sequence of SEQ ID NO: 37;
b) detecting the level of binding between the first polypeptide and the second polypeptide;
c) comparing the binding level of the first and second polypeptides with that detected in the absence of the agent; and d) selecting the agent that reduces the binding level between of the first and second polypeptides as an agent for treating or preventing bladder cancer.

6. The method of claim 5, wherein the first polypeptide comprises the amino acid residues from 1188 to 1718 of SEQ ID NO: 2.